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Cancer is the second leading cause of death in the United States, responsible for ap-
proximately 23% of all deaths according to the National Institute of Health. Of all cancer
patients, approximately 50% undergo radiation therapy as part of their treatment.
Radiation therapy is one of the cancer treatment methods. It uses high-energy radiation
to control and eliminate the tumor by damaging the DNA of the malignant cancer cells.
As radiation is deposited to the cancerous regions, it also affects the cells in the normal
tissues that receive radiation dose in this process, leading to various side effects. Therefore,
radiation therapy treatments must be carefully designed and delivered in order to minimize
the side effects and achieve the desired treatment outcome.
There are two common types of radiation therapy: internal radiation therapy (also known
as brachytherapy) and external beam radiation therapy. Brachytherapy, sometimes called
internal radiation therapy, is a procedure that involves placing radioactive seeds or sources
in or near the tumor, thereby irradiating a very localized area and reducing the radiation
delivered to healthy tissues away from the radioactive material. Throughout the rest of this
thesis we will focus on external beam radiation therapy, for which radiation is delivered from
a treatment machine outside of the patient body. The treatment machine is equipped with a
linear accelerator that accelerates electrons, which can be used to treat the patient directly
1
or to create photons which are used to treat the patient. The radiation is delivered through
a gantry-mounted two-dimensional beam that is aimed at precise areas of the patient body.
Figure 1.1 is a TruebeamTM commercial radiation therapy treatment system produced by
Varian Medical Systems, Inc.
Figure 1.1: A Varian Truebeam radiation therapy treatment system. Image courtesy of
Varian Medical Systems of Palo Alto, California. Copyright 2013, Varian Medical Systems.
All rights reserved.
The amount of radiation used in radiation therapy is measured in Gray (Gy), which
defines the absorption of one joule of radiation energy by one kilogram of matter. While
the total amount prescribed in the treatment depends on many factors including the type
and progression of the cancer, the treatment is usually delivered in a series of daily sessions
spread over several weeks. Each of these sessions is referred to as a fraction. Delivering
the treatment in small daily doses exploits the difference in radiation responses between the
tumor and normal cells, and allows the normal cells to recover between fractions (Halperin
et al. (2008)).
1.2 Intensity modulated radiation therapy
Intensity modulated radiation therapy (IMRT) is an advanced radiation therapy treat-
ment method, for which equipment and treatment planning algorithms have been contin-
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uously developed for more than a decade. With the help of computer-controlled linear
accelerator, the IMRT machine is capable of delivering a high-precision dose distribution
that conforms to the three-dimensional shape of the tumor, and creates sharp dose gradi-
ents (measured by how quickly the dose changes between two adjacent areas with different
dose levels) to effectively avoid the tissues surrounding the tumor (see Intensity Modulated
Radiation Therapy Collaborative Working Group (2001) for an overview of IMRT).
IMRT treatments usually consist of sequential radiation delivery from a (usually small)
number of pre-defined beam angles around the patient body. The use of different beams
allows treatment planners to effectively avoid placing critical organs directly in the path of
radiation targeted at the tumor, and deliver the desired dose distribution collectively from
all beam angles. Selecting the number and orientation of beam angles can be considered as
an optimization branch in and of itself and has spurred the interest of many researchers (see
Stein et al. (1997); Pugachev et al. (2001); Jia et al. (2011) for example). We will focus on
cases for which the selection of the beam angles is performed by experienced planners and
done before the treatment plan optimization.
The IMRT treatment machines are equipped with a device called the Multileaf Collimator
(MLC). The MLC is comprised of dozens of leaf pairs that can stay stationary or move during
the treatment. Individual leaves in the MLC work together to dynamically change the shape
of the exposed beam (also known as aperture). Figure 1.2 (a) illustrates the location of the
MLC inside the gantry and the aperture created with the MLC, and (b) is a view of the
radiation source through the leaves. Note that the fact that the radiation source is a point
leads to the size of the radiation field being different from the size of the MLC aperture, and
the movement speed of the radiation field edge different from the physical speed of the leaves.
We explain the relationship between these quantities in detail in Appendix A. Throughout
the rest of this thesis, we assume that the apertures are MLC openings projected onto the
isocenter plane, which is the plane passing the center of the tumor and parallel to the beam,
and the leaf speed is the projected leaf speed for individual leaves. The planner can easily
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convert these quantities back to those used by the MLC system before the plan is delivered
on the treatment machine. In IMRT treatments, a beam angle usually includes multiple
apertures, each with a distinctive intensity level. The apertures at the same beam angle
are delivered sequentially, and together contribute to an intensity “landscape” for the beam,
which is usually referred to as the fluence map. The ability of IMRT machines to position
the MLC leaves with high precision allows planners to control the intensity of very small
areas of the beams, e.g., 5mm×2mm in size, called beamlets. Determining the intensities
for individual beamlets is one of the most important components of the treatment planning
process, which we will describe below.
(a)
(b)
Figure 1.2: (a): leaves in the MLC block the radiation from the source, creating an irregular
aperture; (b): view of the source from the MLC. Images courtesy of Varian Medical Systems
of Palo Alto, California. Copyright 2013, Varian Medical Systems. All rights reserved.
1.2.1 Treatment planning for IMRT
The treatment planning process for radiation therapy starts with a visualization of the
patient’s internal geometry through the use of Computed Tomography (CT) images. By
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examining the CT images, physicians identify regions that contain cancer tumor that need
to be irradiated, and regions that belong to critical organs which need to be spared in order
to avoid side effects. Figure 1.3 (a) shows the 3D geometry of a prostate cancer patient, and
(b) shows one CT slice that contains the internal structures of the same patient.
(a) (b)
Figure 1.3: (a): 3D geometry of a prostate cancer patient; (b): one CT slice of the same
patient
Based on this anatomical information and the type of cancer, a physician then defines the
appropriate prescription dose for the tumor, as well as a set of criteria used for evaluating
the dose distribution to the tumor, such as “at least 95% of the target volume must receive
the prescription dose”. Usually it is not possible to entirely spare the normal organs of any
radiation dose and deliver the prescribed dose to the tumor due to the proximity of critical
organs, especially when the cancerous cells have invaded into such organs. The physician
will, in addition, prescribe restrictions on the dose to normal organs, such as “no more
than 10% of the brainstem volume can receive more than 10 Gy of dose”. Often times the
restrictions for the target and the critical structures are conflicting with each other, and the
process of determining their specifics usually depends on a combination of clinical experience
and guidelines provided by existing treatment protocols.
The next step in the treatment planning process is to perform dose calculation. A large
number of voxels, obtained by dividing the patient body (usually evenly) into a three-
dimensional grid, as sample points to measure the dose absorbed. The dose calculation
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process determines the dose contribution to different voxels if a beamlet is exposed for cer-
tain amount of time (called the dose deposition coefficient). The IMRT treatment machine
is configured so that the amount of radiation output per unit of time, which we refer to
as monitor unit (MU), is fixed. However, because different tissues have different radiation
absorption, the amount of radiation that reaches each point in the patient body also de-
pends on factors including, among others, the type of tissues the radiation beam passes,
and the sequence they are passed. Therefore the dose calculation process needs to be done
while taking the patient-specific anatomy into account. Common dose calculation meth-
ods include pencil beam (Ahnesjö et al. (1992); Jeleń et al. (2005)), model-based methods
(Mackie et al. (1985); Papanikolaou et al. (1993); Van Esch et al. (2006)), and Monte Carlo
simulation or Monte-Carlo-like algorithms (Rogers and Bielajew (1990); Wang et al. (1998);
Jia et al. (2010); Fogliata et al. (2011)). Once the dose calculation process is completed, the
dose deposition coefficients are used as input parameters in the treatment plan optimization
problem.
1.2.2 Fluence map optimization
The treatment plan optimization problem, of which the basic type is called fluence map
optimization, determines the optimal fluence map from all beam angles that collectively
deliver the treatment plan that can best achieve the prescription dose for the target, and
meet or exceed the normal tissue requirements as much as possible. The fluence map opti-
mization is done by solving an “inverse” planning problem, which starts with a desired dose
distribution and ends with the beamlet intensities that can best achieve this distribution:
• V : the set of all voxels
• I: the set of all beamlets
• dij: the dose deposition coefficient corresponding to beamlet i ∈ I and voxel j ∈ V
• xi: decision for the intensity of beamlet i ∈ I
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• zj: decision for the dose delivered to voxel j ∈ V








dijxi ∀j ∈ V
xi ≥ 0 ∀i ∈ I.
Here we make the reasonable assumption that the dose delivered from different beamlets
is additive. The objective function used in the optimization problem needs to be able to
properly capture the different requirements we have for different structures, as well as to
address the trade-off between structures. Researchers have proposed various functional forms
for the objective function for this purpose, including:
• tumor control probability (TCP) and normal tissue complication probability (NTCP)
(Wolbarst (1984); Lyman (1985); Zaider and Minerbo (1999)). These methods first fit
the dose response data of a single cell to a mathematical function (which usually has a
sigmoidal shape), then derive the probability of having no clonogenic cells in the target,
and the probability of not causing complications to the normal organs, after receiving
a (homogeneous or inhomogeneous) dose. For the target we want the probability to be
as close to 1 as possible, and for the normal organs as close to 0 as possible.
• equivalent uniform dose (EUD) and generalized EUD (gEUD) (Niemierko (1997, 1999)).
The EUD method establishes an equivalent homogeneous dose for an inhomogeneous
dose distribution: if the EUD is uniformly distributed to the entire target volume, the
number of surviving clonogens will be the same as that under the corresponding inho-
mogeneous dose distribution. This concept was later extended to make it applicable to
critical organs, and its name changed to gEUD. The gEUD has often been a method
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of choice and used by many researchers since its introduction (Choi and Deasy (2002);
Thieke et al. (2003); Wu et al. (2005)).
• voxel-based convex function. Rather than trying to model the biological effects, this
family of approaches measures the quality of the treatment plan by the value of a
convex function at the dose delivered to each voxel, and use the average of such function
values as the objective function. The resulting function can thus be separated for each
voxel, making it simple to work with mathematically in the optimization problem.
Typical choices for the convex function include absolute value function and least square
functions.
Romeijn et al. (2004) showed that optimizing with most of the above objective functions
or a combination of them will lead to the same treatment plan as optimizing with a cor-
responding voxel-based convex objective function. Therefore, we will use structure-specific,
voxel-based functions as the objective function in our optimization models. It provides sim-
plicity in the optimization problem, and can generate high quality treatment plans (see, for
example, Shepard et al. (1999); Romeijn et al. (2003)).
Besides the simple constraints used in (FMO) above, investigators have utilized con-
straints of different types to enforce restrictions on the intensities and/or voxel dose, or to
achieve a desired dose distribution. Common examples of such constraints include minimum,
maximum, or average voxel dose in a certain structure, constraints based on biological crite-
ria such as TCP and EUD, and excess or shortfall criteria (see Romeijn and Dempsey (2008)
for an overview of related topics).
The solution to problem (FMO) provides us with a vector of beamlet intensities, as well
as the dose delivered to each voxel given this intensity profile. Figure 1.4 shows a fluence
map consisting of intensities of beamlets in seven different beam angles, where brighter colors
corresponds to higher intensities. The beamlet intensities are subsequently fed into a post-
processing step (also called the leaf sequencing step). The leaf sequencing step ensures that
the fluence map with irregular intensities can be delivered by the MLC by converting it into
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a number of apertures, each with uniform intensity. It is desirable that the beam-on time
(the time the source is turned on in the treatment) and/or the number of total apertures
is minimized as a result of the leaf sequencing step (see Crooks et al. (2002); Taşkın et al.
(2010)).
Figure 1.4: Illustration of a fluence map consisting of intensities of beamlets in seven different
beam angles
1.2.3 Evaluating a treatment plan — Dose Volume Histogram
The most common way of evaluating the quality of a treatment plan, or equivalently
the corresponding dose distribution, is by examining the associated Dose Volume Histogram
(DVH). DVH is a method for summarizing the 3-D dose distribution in different structures
with a set of 2-D curves, and it has been one of the most important tools in the process
of evaluating IMRT treatment plans. Figure 1.5 is a typical DVH plot for prostate cancer.
Each curve on the plot represents an individual structure, and a point on a curve represents
a dose value (horizontal axis) and the corresponding percentage of volume (vertical axis) in
the corresponding structure that receive dose above that value. We can visualize on the DVH
many common constraints and criteria that impose upper or lower bounds on the percentage





























Figure 1.5: A typical DVH plot for prostate cancer treatment plan
1.3 Volumetric modulated arc therapy
Volumetric modulated arc therapy (VMAT) is a new radiation therapy treatment modal-
ity that delivers radiation while the gantry and the attached radiation source are in contin-
uous motion. VMAT allows the source output (dose rate), gantry speed and the aperture
shape to simultaneously vary. As opposed to IMRT treatments which require setup time
in between consecutive beam angles, VMAT treatments are usually delivered in one or two
continuous rotations (also referred to as arcs), therefore drastically reducing the treatment
time. Since Yu (1995) introduced the intensity modulated arc therapy, which later led to
the full capacity VMAT systems, VMAT has attracted the attentions of both the medical
and the operations research communities. While VMAT delivery equipments and treatment
planning algorithms are still being actively developed, clinical studies (see, for example,
Cozzi et al. (2008); Bertelsen et al. (2010); Matuszak et al. (2010)) that compare VMAT
to traditional IMRT and other types of treatment modalities with existing commercial sys-
tems have found that VMAT is capable of both substantially reducing the overall treatment
time and providing comparable or superior treatment plan quality. As a result of the shorter
treatment delivery time, clinics can benefit from increased throughput and alleviated patient
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discomfort during the treatment. Moreover, reduced delivery time also means the treatments
are less susceptible to intra-fraction motions, i.e., motions that happen during the treatment,
such as breathing and organ fill-up/depletion, therefore further improving the quality of the
actual treatments.
The concept of a control point is introduced to help treatment planners to control and
describe a VMAT treatment. Although decisions involved in a treatment, namely gantry
speed, dose rate and aperture shape, need to be specified at every angle along the gantry
trajectory, doing this will quickly make the planning problem intractable. Instead, it is a
common practice in research as well as in commercial planning systems to restrict these
decisions to be made at only a pre-determined set of angles, namely the control points. The
treatment machine is configured so that in between consecutive control points, the gantry
speed, dose rate as well as aperture shape transition smoothly. Figure 2.2 shows a sample
set of control points along a sample treatment arc. Note that the treatment arc can utilize
the entire 360◦ circle, or can have a small gap under the treatment couch for reasons such
as to avoid delivery from under the couch, and to avoid placing a critical organ directly in
between the radiation source and the target.
Figure 1.6: The set of control points along the treatment arc. The circle in the middle
represents the patient on the treatment couch.
Despite the advantages of the VMAT technology, treatment planning for VMAT is much
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more challenging than for IMRT. Because VMAT utilizes a much larger set of angles, the
amount of data involved in the treatment planning process, as well as the efforts required
in formulating and solving the plan optimization problem are much larger. Moreover, the
continuous gantry motion adds restrictions on the relationship between the machine param-
eters used at different control points. In particular, the change in gantry speed from one
control point to a subsequent one must be compatible with the treatment machine’s physical
acceleration/deceleration limits, and the change in aperture shapes cannot be too drastic
between two control points. Therefore, special care must be taken when designing treatment
plans for VMAT. We will discuss an optimization algorithm for VMAT in Chapter II.
1.3.1 VMAT with constant gantry speed and dose rate
IMRT machines equipped with conventional linear accelerator and MLC are able to
deliver rotational arc therapy that resemble VMAT treatments. This type of treatment has
less flexibility compared to full VMAT, allowing only constant gantry speed and dose rate
during the treatment. However, like VMAT, it has the freedom to dynamically change the
aperture shapes through the utilization of the MLC. It was first referred to as the Intensity
Modulated Arc Therapy (IMAT) or Dynamic Arc Conformal (DAC) radiotherapy. Research
efforts and clinical experiments on IMAT/DAC were the earliest of those on VMAT before
the invention of dedicated VMAT treatment systems (Yu (1995); Ma et al. (2001); Verellen
et al. (2002); Crooks et al. (2003); Cao et al. (2007)). In fact, some have used the term
IMAT to refer to treatments methods in which dose rate and/or gantry speed can change
dynamically. To avoid confusion, we refer to VMAT treatments that only allow constant
gantry speed and dose rate as VMATC in the rest of this thesis.
Even though VMATC treatments lack some of the most important capabilities of VMAT,
especially those that allow the gantry speed and dose rate to dynamically change during the
treatment, fully realizing its potentials can still be beneficial. Being able to deliver the
treatment in one rotation potentially allows the delivery time to be reduced, thus allowing
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clinics with conventional IMRT systems to enjoy many of the benefits of VMAT treatments
and avoid the large capital expenditure required to upgrade to the full VMAT systems.
In spite of the similarities between VMAT and VMATC treatments, VMATC’s lack of the
ability to change gantry speed and dose rate substantially limits our choice of apertures in the
planning process, and poses difficulties that need to be addressed with substantially different
methods from those used for VMAT. In Chapter III we propose and study optimization
algorithms for the VMATC treatment planning problem.
1.4 Uncertainty and adaptive radiation therapy
The presence of uncertainty in the delivery of radiation therapy treatments often causes
the treatment quality to be compromised and the actual dose distribution to deviate from
the planned one. Setup errors in the positioning of the patient, changes in patient anatomy
due to the changed progression of the disease, which happen in between fractions, as well
as intra-fraction uncertainty that are typically caused by, e.g., breathing and bowel motions
during the treatment all contribute to uncertainties in the treatment.
The use of immobilization devices have been explored in clinics to control and reduce
uncertainty (Bentel (1998)). However, these aids cannot fully eliminate small errors and
motion that affect the position of the patient relative to the radiation beams. The traditional
approach to dealing with this uncertainty is by expanding the Clinical Target Volume (CTV),
which is delineated from the CT images of a stationary patient, by an internal margin to
produce the Internal Target Volume (ITV), and a margin to form the Planning Target
Volume (PTV). In the treatment plan optimization the PTV is used as the target to account
for uncertainties during the treatment. However, many researchers have shown that the use
of margin may not achieve the desired target coverage, and may introduce overdosing of the
organs surrounding the PTV (for example, Olafsson and Wright (2006); Men et al. (2011)).
Alternatively, researchers have applied various techniques in stochastic optimization, dy-
namic programming and robust optimization in order to explicitly incorporate uncertainty
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into the plan optimization problem (see, for example, Löf et al. (1999); Baum et al. (2006)).
However, it is important to ensure that in solving the optimization models, the solution
does not only depend on extreme cases but also takes the majority of possible scenarios into
account, and that the optimization models are not oversimplified in the solution process.
In Chapter IV we propose a stochastic optimization based model, and a solution procedure
that can guarantee high quality solutions.
Recent advancements in imaging technology has made it possible to monitor and record
the information associated with the treatment delivery in each fraction, such as fraction-to-
fraction setup variation and organ deformation, as well as to reconstruct in vivo the 3D dose
distribution for a given fraction (Partridge et al. (2002); Yang et al. (2007)). This additional
information allows researchers and practitioners to not only verify the correct delivery of
the planned treatment, but also review and correct any discrepancies in the actual dose
distribution. We extend our stochastic optimization based model to adaptive treatments,
where plan optimization is performed during the treatment course to account for the actual
delivered dose.
1.5 Contributions and outline of the thesis
The rest of this thesis is organized as follows:
• Chapter II discusses a method for solving the treatment plan optimization problem for
VMAT. We propose a new column generation based algorithm that takes into account
bounds on the gantry speed and dose rate, as well as an upper bound on the rate
of change of the gantry speed, in addition to MLC constraints. To our knowledge,
the constraints have not all been considered in any existing research. The algorithm
iteratively adds one aperture at each control point along the treatment arc. In each
iteration, a restricted problem optimizing intensities at previously selected apertures
is solved, and its solution is used to formulate a pricing problem, which selects an
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aperture at another control point that is compatible with previously selected apertures
and leads to the largest rate of improvement in the objective function value of the
restricted problem. Once a complete set of apertures is obtained, their intensities are
optimized and the gantry speeds and dose rates are adjusted to minimize treatment
time while satisfying all machine restrictions. Comparisons of treatment plans obtained
by our algorithm to idealized IMRT plans of 177 beams on 5 clinical prostate cancer
cases demonstrate high quality with respect to clinical dose-volume criteria. For all
cases our algorithm yields treatment plans that can be delivered in around 2 minutes.
Our approach can be easily modified to accommodate a range of other settings of the
VMAT treatment machine.
• Chapter III considers the VMATC treatment plan optimization problem. We specif-
ically consider the simultaneous optimization of the constant gantry speed and dose
rate, in addition to the optimization of leaf positions. We propose two algorithmic
frameworks for (approximately) solving the optimization problem. One framework
separates leaf setting optimization, which chooses the leaf positions given a dose rate
and gantry speed combination, from the optimization of the constant dose rate and
gantry speed. The framework searches for a dose rate and gantry speed combination
that leads to the best plan qualities. The alternative framework applies alternating
optimization to dose rate and gantry speed and the leaf settings. We compare both
optimization frameworks on clinical patient cases, and compare the resulting VMATC
plans to the VMAT plans. Our results show that VMATC is capable of producing
very high quality treatment plans compared to VMAT, albeit at the expense of long
computation time and higher total radiation output from the source.
• Chapter IV focuses on the optimization of IMRT treatment plans under inter-fraction
uncertainty. We propose a stochastic model that incorporates the uncertainty in dose
delivered in one fraction, as well as over the treatment course. Instead of solving
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this problem directly, which easily becomes intractable for real-world cases, we draw
samples from the error distribution and solve the sample average approximation prob-
lem. We apply a dynamic sampling procedure that establishes bounds on the objective
function, therefore enabling us to find verifiably high quality, approximate solutions
to the optimal solution. We show with clinical prostate cancer cases that using the
stochastic model can improve the treatment plan quality compared to the conventional
approach. If delivered dose information is available during the treatment course, we
can extend our solution framework to adaptive radiation therapy optimization prob-
lems. However, in the adaptive optimization problems the solution puts more emphasis
on the per-fraction target coverage, and usually results in higher dose to the surround-
ing structures. This effect needs to be taken into account when using this model in
adaptive treatment planning.
• In Chapter V we conclude the thesis, and propose directions for future research.
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CHAPTER II
VMAT Treatment Plan Optimization
2.1 Introduction
Rotational delivery of Intensity Modulated Radiation Therapy (IMRT) was first proposed
by Yu (1995) as Intensity Modulated Arc Therapy (IMAT). This radiation therapy treatment
modality delivers radiation while the gantry rotates around the patient in one or more arcs
while, at the same time, field shapes (apertures) are formed to modulate fluence using a multi-
leaf collimator (MLC) system. Recently, this modality has gained popularity and interest due
to the introduction of several commercially available implementations, and is now usually
referred to as Volumetric Modulated Arc Therapy (VMAT). These advances have also made
it possible to dynamically change the dose rate and gantry speed. As compared to more
standard IMRT treatments, which use a relatively small number of fixed beam directions,
VMAT has the potential to significantly reduce treatment time. This has the additional
benefits of decreasing patient discomfort, mitigating intrafraction motion uncertainties, and
increasing the utilization rate of the equipment.
Since the conception of VMAT, researchers have investigated inverse planning techniques
as well as methods to make VMAT plans deliverable in one single arc. Various studies utilized
techniques including simulated annealing (Cameron (2005); Earl et al. (2003)) and trans-
formation of an IMRT treatment plan (Crooks et al. (2003)) to design VMAT treatments.
These studies showed that, with constant gantry speed and dose rate, either multiple arcs or
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an excessively long time for a single arc are required to deliver a high-quality treatment. In
a theoretical study, Bortfeld and Webb (2009) compared single-arc VMAT treatment to tra-
ditional IMRT on a phantom and argued that single-arc VMAT may not be able to replicate
the optimal intensity profile without intensity modulation at individual angles – a claim that
was denied in a response by Otto (2009). Today the potential quality of VMAT treatment
plans is generally believed to be comparable to IMRT treatment plans (Palma et al. (2008);
Verbakel et al. (2009)).
The nature of VMAT treatments makes the treatment plan optimization problem much
more complex than an IMRT treatment plan optimization problem due to the continuous
nature of the gantry motion, gantry speed constraints, dose rate constraints, and MLC
leaf speed constraints. Even when the set of angles is discretized, exact methods quickly
become intractable. Hence the literature has exclusively focused on simplifications of the
model and/or heuristic solution approaches. Many approaches to the VMAT treatment plan
optimization problem rely on converting an IMRT plan in some fashion. Luan et al. (2008),
Shepard et al. (2007), and Wang et al. (2008) proposed algorithms that rely on (i) first
identifying an optimal IMRT treatment plan using 10◦-spaced beam directions and then (ii)
producing a deliverable VMAT plan by minimizing the difference between the sequenced
and the ideal IMRT fluence maps. Cao et al. (2009) started the treatment planning process
by performing IMRT planning with direct machine parameter optimization, which directly
optimizes aperture shapes and weights. They then used a simulated annealing based arc
sequencer to convert the resulting fluence maps into deliverable VMAT plans while again
minimizing the difference between the IMRT and VMAT fluence maps. Craft et al. (2011)
performed IMRT optimization on 2◦-spaced beam angles and, noting that adjacent fluence
maps were similar, used a combination of beam merging and sliding window leaf sequences to
obtain a VMAT deliverable plan whose quality is close to the “ideal” IMRT plan. However,
their observation that adjacent fluence maps in the high-resolution IMRT treatment plan are
similar appears to depend strongly on the particular treatment plan optimization algorithm
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employed, so the approach may not be robust to changes in treatment plan evaluation criteria
that would require using a different algorithm.
Several approaches to VMAT treatment plan optimization use the concept of control
points, which represent beam directions along the arc where machine parameters such as
gantry speed, aperture shape, and dose rate are controlled. Between control points, the
machine parameters are then either kept constant or interpolated in some fashion. Otto
(2008) proposed a simulated annealing algorithm that adds control points sequentially and,
in each iteration, randomly samples aperture weights and shapes. Bedford (2009) discretized
an IMRT fluence map into multiple intensity levels and assigned each level to a control point
close to the corresponding angle in the IMRT plan. A subsequent local search procedure
attempts to improve leaf positions and segment weights. Bzdusek et al. (2009) started with
an IMRT plan on a coarse set of angles, then generated two apertures to approximate each of
the fluence maps and placed these at predetermined control points. Additional control points
were assigned interpolations of these apertures, and the remaining machine parameters were
calculated in a subsequent optimization step. Gözbasi (2010) formulated the problem as a
large integer programming model, but for tractability reasons resorted to grouping beamlets
and solved a series of approximate problems. Unfortunately, the required computation time
of the algorithm are still impractical and the algorithm also failed to consistently provide
clinically acceptable results on their test cases.
Finally, Men et al. (2010b) proposed a column generation based approach which se-
quentially adds aperture shapes at control points while ensuring that each newly generated
aperture is compatible with previously chosen ones. However, no bounds on the dose rate
were taken into account, and gantry speed was considered to be constant. In this chapter
we formalize and extend this approach to explicitly take the following physical restrictions
into account during the course of the algorithm:
• apertures at consecutive control points must be compatible, i.e., the leaves in individual
rows of the MLC must be able to finish their transition from the previous aperture to
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the next aperture before the gantry reaches the next control point;
• restrictions on machine parameters, such as upper and lower bounds on the gantry
speed and dose rate, as well as the upper bound on the rate of change of the gantry
speed must be obeyed.
Although some of the algorithmic approaches proposed in the literature and discussed above
account for some of these restrictions by either explicitly incorporating them into the treat-
ment plan optimization or by modifying the optimized plan into one that satisfies them in
a post-processing step, to the best of our knowledge none incorporates all of the restric-
tions explicitly in the treatment plan optimization process. Our algorithm is implemented
using the Compute Unified Device Architecture (CUDA) to take advantage of the parallel
processing power of the Graphic Processing Unit (GPU).
2.2 The VMAT optimization model
Let K denote the total number of (not necessarily equispaced) control points along one
or more treatment arc(s) (in case of multiple arcs, K represents the total number of control
points along all arcs, which will be ordered so that the first control point on the second arc
succeeds the last control point on the first arc, etc.). We associate with each control point k
an aperture Ak, a dose rate rk (in MU/second), and a gantry speed sk (in degrees/second).
In addition, we can express the fluence rate (in MU/degree) at control point k as yk = rk/sk.
Note that each control point represents a snapshot of the continuous gantry rotation, i.e.,
rk, sk, yk, and Ak represent the state of the treatment machine as the gantry passes through
control point k. For convenience, we will add a dummy control point 0 in the beginning of
the arc. For tractability we will then calculate the dose delivered to each voxel by making the
approximation that the aperture, dose rate, and gantry speed (and hence fluence rate) are
constant throughout the arc spanning from one control point to the next. Note in particular
that this means that we do not need to specify any of the variables at the dummy control
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point 0. If the angular distances δk between pairs of control points k and k − 1 are small,
then this approximation will be sufficiently accurate (Otto (2008)).
The gantry speeds and apertures specified at consecutive control points need to be com-
patible with each other. This compatibility requirement derives from the characteristics of
the MLC system used to form the apertures during the treatment. As the gantry travels
from control point k− 1 to control point k, the leaves of the MLC system need to shift from
positions prescribed by aperture Ak−1 to those prescribed by aperture Ak. Since the speed
of such leaf movement is bounded, the time spent by the gantry moving between the control
points needs to be sufficiently large (and hence its speed sufficiently small) to allow for the
required leaf movement to take place. We will denote the maximum gantry speed that will
allow aperture A′ at control point k to be reached from aperture A at control point k − 1
by SUk−1,k(A,A
′) for k = 1, . . . , K, where, for convenience, SU0,1(A,A
′) = ∞ for all pairs of
apertures A and A′.
In addition to the discretization parameters δk (k = 1, . . . , K), there are several other
machine parameters that need to be taken into account. First, a VMAT delivery machine
may have upper and lower bounds on gantry speed (denoted by SU and SL), and an upper
bound on dose rate (denoted by RU). Furthermore, there typically is an upper bound on the
rate of change in speed that the gantry can sustain, which may be given per degree or per
control point. We will denote the upper bound on the change in speed between control points
k− 1 and k by ∆Sk. Finally, we let A denote the set of all apertures that are deliverable by
the MLC system. In particular, we will assume that left and right leaves within each pair can
be positioned at any non-overlapping continuous points within their range, and that motion
is independent between leaf pairs. In particular, we assume that there are no interdigitation
constraints. After formulating our base model and developing our algorithm, we will discuss
how additional constraints, such as a lower bound on dose rate, independent bounds on the
fluence rate, and interdigitation constraints, can be incorporated into our solution approach
when necessary.
21
Finally, let the discretized set of voxels be V , and denote the delivered dose distribution
by z = (zj : j ∈ V)>, where zj is the total dose delivered to voxel j ∈ V . The quality of
the dose distribution z is evaluated using an objective function F : R|V| → R. Under our
approximation zj is equal to the sum of the doses delivered to the voxel from all control
points. Moreover, since the delivered dose is linear in fluence, it is convenient to denote the
dose received by voxel j ∈ V from aperture A ∈ A at control point k at unit fluence by
Dkj(A) (k = 1, . . . , K).
The complete VMAT optimization model, which we refer to as the full problem (FP),
then reads:









k = 1, . . . , K
|sk − sk−1| ≤ ∆Sk k = 2, . . . , K
sk ∈ [SL, SU ] k = 1, . . . , K
rk ∈ [0, RU ] k = 1, . . . , K
sk ≤ SUk−1,k(Ak−1, Ak) k = 1, . . . , K (2.1)
Ak ∈ A k = 1, . . . , K,
where the terminal aperture A0 in (2.1) can be chosen arbitrarily and is added for convenience
only.
We can simplify this model by first noting that for any feasible solution s, r,y, z and
(Ak : k = 1, . . . , K) of (FP) we can obtain another feasible solution with the same apertures
and the same values of y and z (and hence the same objective function value), but with
all the gantry speeds at their lower bound value SL by scaling the dose rates by a factor of
SL/sk ≤ 1, k = 1, . . . , K, to compensate. As a result, we can eliminate the gantry speed
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variables from the model. In addition, we can then replace the upper bound constraints on
the dose rates by upper bounds on fluence rate and eliminate the dose rate variables as well.
The problem thus reduces to the following master problem (MP):





Dkj(Ak) δk yk j ∈ V (2.2)
yk ∈ [0, Y U ] k = 1, . . . , K (2.3)
SL ≤ SUk−1,k(Ak−1, Ak) k = 1, . . . , K (2.4)
Ak ∈ A k = 1, . . . , K, (2.5)
where Y U ≡ RU/SL. We will refer to (MP) as the master problem, for reasons made clear in
the following section. By construction, for any feasible solution to (MP) we can construct an
equivalent feasible solution to (FP), in the sense that it has the same apertures and values
of y and z, by setting sk = S
L and rk = yk · sk for k = 1, . . . , K. Moreover, there may
be several combinations of gantry speeds and dose rates that lead to equivalent solutions to
(FP), and some may be more desirable than others, e.g., due to shorter treatment times. We
will discuss this in more detail in Section 2.7.
Note that (MP) is not convex because of the nonlinearities associated with the apertures
in constraints (2.2) — (2.5). Therefore, instead of solving problem (MP) exactly, we propose
a column generation based algorithm.
2.3 An algorithm for solving (MP)
Our proposed algorithm starts with a dose distribution z = 0 and without an aperture
specified at any of the control points. The algorithm then proceeds by, in each iteration,
attempting to improve the current treatment plan and dose distribution by selecting an
aperture at one of the control points for which none has been specified yet (that is, generating
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a column in constraint (2.2) of (MP)), and terminates when a completely specified treatment
plan is obtained. In any given iteration, which is characterized by a set C ⊆ {1, . . . , K} of
control points and the corresponding collection of apertures {Āk, k ∈ C}, we optimize
fluence rates of these apertures by solving the so-called restricted master problem (RMP).
The RMP is constructed so that a feasible solution to this problem implicitly provides a
deliverable plan that can be fully specified by feasibly completing the sequence of apertures
while retaining the current aperture fluence rates (in particular, yk = 0 for k 6∈ C). The
optimal solution to the RMP then defines the so-called pricing problem (PP) which is used
to select the next control point and aperture to be added to the plan. The intuition behind
the PP is that, relative to the current solution, each candidate aperture at each control point
k 6∈ C has an associated price which is defined as the rate of improvement in the objective
function value if the fluence rate of that aperture is increased (from its current value of 0).
The pricing problem then finds the control point/aperture combination that has the best
price. In contrast with direct aperture optimization (DAO) for IMRT treatment planning
(Preciado-Walters et al. (2004); Romeijn et al. (2005); Shepard et al. (2002)), only a single
aperture is added for each control point. This makes our algorithm heuristic in nature and,
in particular, a greedy heuristic.
More formally, our algorithm can be described as follows:
Column generation based greedy heuristic for (MP)
Step 0. Set C = Ø and z̄ = 0.
Step 1. Use the information on the current treatment plan (control points C, apertures Āk
for k ∈ C, and dose distribution z̄) to formulate and solve an instance of the PP.
Step 2. If the optimal value of the PP is nonpositive, go to Step 5. Otherwise, denote the
optimal solution to the PP by c̄ and Āc̄, and replace C by C ∪ {c̄}.
Step 3. Solve the instance of the RMP associated with C and Ak = Āk, k ∈ C.
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Step 4. Remove apertures in the set C={k ∈ C : yk = 0}, i.e., set C ← C\C.
Step 5. If |C| < K, return to Step 1.
Step 6. If necessary, complete the treatment plan by identifying feasible apertures (which
will have fluence 0) at control points c 6∈ C, and denote the final set of fluence rates
by ȳk (k = 1, . . . , K).
Figure 2.1 provides a graphical representation of the structure of this algorithm.
In the remainder of this section, we will provide additional details on Steps 1, 2 and
3 of this algorithm in Sections 2.4 and 2.6. Section 2.7 discusses obtaining a solution to
(FP) based on the solution to (MP) returned by our algorithm. Section 2.8 discusses how
additional constraints on the setting of the VMAT delivery machine can be incorporated into
(FP) formulation and our solution. Finally, we present experiments and results in Section
2.9.
2.4 Restricted master problem
At each iteration of the algorithm we obtain the RMP from (MP) by fixing the apertures
Ak = Āk for all control points in the current set C ⊆ {1, . . . , K} and setting the fluence rates
yk = 0 for all control points k 6∈ C. The RMP then reads:





Dkj(Āk) δk yk j ∈ V
yk ∈ [0, Y U ] k ∈ C.
(2.6)
(RMP(C)) can be thought of as a restriction of (MP) in that it considers a subset of control
points, and considers the apertures Āk, k ∈ C, to be fixed and given. Note that (RMP(C))
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Figure 2.1: Flow chart for the column generation based greedy heuristic for (MP)
is a nonlinear optimization problem with linear constraints, and it is a convex optimization
problem provided that F is a convex function.
Recall that any feasible solution to (RMP(C)) should correspond to a deliverable plan
that can be fully specified by completing the sequence of apertures at control points k 6∈ C
in a way that is compatible with apertures Āk, k ∈ C, and setting yk = 0, k 6∈ C. To
ensure that this is indeed the case, the set of apertures Āk, k ∈ C in the restricted problem
should satisfy the following condition. For all k ∈ C, let k− be the predecessor of k in C, i.e.,
k− = max{k′ ∈ C : k′ < k}, where k− ≡ 0 if k = min{k′ : k′ ∈ C}. Any feasible solution to
(RMP(C)) for any C ⊆ {1, . . . , K} can be extended to a feasible solution to (MP), provided
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that
SUk−k(Āk− , Āk) ≥ SL, k ∈ C. (2.7)
Here we have generalized the notation of (FP) and (MP) by denoting the maximum gantry
speed that will allow aperture A′ at control point k′ to be reached from aperture A at control
point k < k′ by SUkk′(A,A
′) (where again, for convenience, we will let SU0,k(A,A
′) =∞ for all
pairs of apertures A and A′ and all k = 1, . . . , K). In Section 2.6 we will discuss in detail the
pricing problem designed to ensure that the apertures added at each iteration of the column
generation algorithm satisfy (2.7).
If, from solving (RMP(C)), any aperture Āk (k ∈ C) has intensity rate 0, we can remove
these apertures without affecting the plan quality. Apertures added early in the algorithm,
when the total delivered dose is relatively low, are likely to have large openings and/or high
fluence rates. As the algorithm progresses, these apertures are no longer effective, their
fluence rates are set to 0 in the (RMP(C)) and they are subsequently removed. Since only
one aperture can be used at every control point, removing these redundant apertures allows
better ones to be added later on in the column generation process. Let C={k ∈ C : yk = 0}
be the set of control points that have redundant apertures, after solving (RMP(C)), we set
C ← C\C.
2.5 Intermediate stage master problem
The RMP is solved at every iteration to find the fluence rate for apertures k ∈ C. However,
our algorithm is not complete before we have a procedure to search for the next improving
aperture. We examine the master problem at an intermediate stage, where only control
points k ∈ C have apertures specified, and all possible apertures are included for control
points k /∈ C. This problem is not solved during the optimization process, rather we use
its associated first order optimality conditions to find the rate of improvement in objective
function value per unit fluence rate for apertures at control points k /∈ C. This information
will help us identify the best aperture to add to the treatment plan.
27
Note that for control points k /∈ C, we associate an fluence rate value with every possible
aperture, therefore there will be several fluence rates associated with one control point, and
thus constraints (2.2) and (2.3) will have to be modified to accommodate this. Let
ykA k /∈ C, A ∈ A.
represent the fluence rate for aperture A ∈ A at control point k, we can use∑
A∈A
ykA k /∈ C
instead of yk in (2.2) and (2.3). The intermediate stage master problem can then be formu-













Dkj(A) δk ykA j ∈ V (πj)
yk ≥ 0 k ∈ C (ρk)
yk ≤ Y U k ∈ C (γk)∑
A∈A
ykA ≤ Y U k /∈ C (γk)
ykA ≥ 0 k /∈ C, A ∈ A (βk(A))
We associate the set of constraints in (MI) with dual variables πj (j ∈ V), ρk (k ∈
C), γk (k ∈ {1, . . . , K}), and βk(A) (k /∈ C, A ∈ A). The first order optimality conditions,
which are necessary and sufficient for optimality for this problem (see, for example, Bazaraa




j ∈ V (2.8)
ρk − γk = −
∑
j∈V
πj Dkj(Āk) δk k ∈ C (2.9)
γk (yk − Y U) = 0 k ∈ C (2.10)
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ρk · yk = 0 k ∈ C (2.11)
− γk + βk(A) = −
∑
j∈V




ykA − Y U) = 0 k /∈ C (2.13)
βk(A) · ykA = 0 k /∈ C, A ∈ A
γk ≥ 0 k ∈ {1, . . . , K}
ρk ≥ 0 k ∈ C
βk(A) ≥ 0 k /∈ C, A ∈ A (2.14)
Observe that the optimal solution to problem (RMP(C)), (ȳ, z̄), and the corresponding
dual variables πj(z̄)(j ∈ V), ρk, γk (k ∈ C) satisfy conditions (2.8) — (2.11). We can set
variables ykA = 0 (k /∈ C, A ∈ A), and set γk = 0 (k /∈ C), and verify if (2.12) and (2.14) are
satisfied. If so, the current solution is already optimal for problem (MP). Otherwise, (2.12)




πj(z̄)Dkj(Ak) δk k /∈ C, A ∈ A. (2.15)
Care needs to be taken to ensure that any aperture we select for k /∈ C is compatible with
the apertures in control points k ∈ C. Next we explain in detail how improving apertures
are chosen so that compatibility constraint (2.4) is satisfied.
2.6 Pricing problem
2.6.1 Pricing problem derivation
Suppose we were to add aperture A ∈ Ak at a control point k 6∈ C, where Ak ⊆ A is a
set of deliverable apertures that can feasibly be added to the current treatment plan. From
the discussion in Section 2.5, the rate of improvement (i.e., decrease) in objective function
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where (πj(z̄) : j ∈ V)> = π(z̄) ≡ −∇F (z̄). Our strategy will be to select a control point k







In order to ensure that solutions to (PP) satisfy condition (2.7), we need to specify the
set Ak in such a way that
Ak ⊆
{
A ∈ A : SUk−k(Āk− , A) ≥ SL, SUkk+(A, Āk+) ≥ SL
}
≡ AUk .
The choice of Ak ⊆ AUk in the PP dictates a tradeoff in the behavior of our heuristic
algorithm. On the one hand, choosing a smaller set Ak at the current iteration results in
lesser flexibility in the current selection of apertures. On the other hand, this can potentially
allow for more flexibility in later iterations of the heuristic. We will consider the following
family of potential choices for Ak in (PP), parameterized by a lower bound s on the speed
between two control points:
Ak(s) =
{
A ∈ A : SUk−k(Āk− , A) ≥ s, SUkk+(A, Āk+) ≥ s
}
for s ≥ SL. (2.16)
It is easy to see that Ak(s
′) ⊆ Ak(s) whenever s′ ≥ s, with Ak(SL) = AUk . Note also
that, although the choice of s does not explicitly determine the final gantry speed used at
different control points, because it affects the selection of apertures Ak(s), it implicitly affects
the final gantry speed and thus the delivery time. We will explore the impact of the choice
of parameter s on the overall performance of the algorithm in our experiments.
If the optimal value of (PP) is non-positive, we conclude that the current solution cannot
be improved by adding any aperture at any control point (at least in the framework of our
algorithm). In this case, the algorithm will be terminated (see Step 2), and fluence rates at
control points k 6∈ C will remain at zero. However, if an improving control point/aperture
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are found, the algorithm will proceed to Step 3.
2.6.2 Solving the pricing problem
We will now describe a solution approach for the pricing problem (PP). First, it is easy to
see that this problem decomposes into a collection of independent problems for the different






where we have also eliminated the scaling constant δk.
Next, in the absence of interdigitation constraints, we can decompose (PP(k)) by MLC
row. In particular, if the MLC system consists of M leaf pairs, we can represent any aperture
A ∈ A as a collection of leaf settings for its individual rows. Let us denote an aperture by
A = (a1, . . . , aM), where am ∈ α describes the leaf settings of MLC row m of aperture A, and




a : SUk−k(āk−m, a) ≥ SL, SUkk+(a, āk+m) ≥ SL
}
, (2.17)
where ācm is the mth row aperture of Āc at control point c ∈ C and, with a slight abuse of
notation, SUk′k(a, a
′) denotes the maximum gantry speed that will allow row aperture a′ of
aperture A′ at control point c to be reached from row aperture a at control point k′ < k.
Let Dkmj(a) denote the dose received by voxel j ∈ V from row aperture a ∈ α in row m and
control point k at unit fluence rate, with Dkj(A) =
∑M
m=1 Dkmj(am). The pricing problem






Recall that we would like to consider the family of feasible regions Ak = Ak(s) defined
by (2.16) for s ≥ SL. The corresponding family Akm(s) of feasible regions for (PP(km)) is
Akm(s) =
{
a : SUk−k(āk−m, a) ≥ s, SUkk+(a, āk+m) ≥ s
}
for s ≥ SL. (2.18)
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Let us analyze the structure of these sets in more detail. Any row aperture a can be char-
acterized as a pair of leaf settings (`, r), where 0 ≤ ` ≤ r ≤ N are the positions of the left
and right leaf, respectively (N , which we assume to be integer, is the range of the MLC
row). Furthermore, let v denote the maximum leaf speed (in distance/second, with the unit
of distance depending on the choice of N). Then, for k < c,{










k′=c δk′ . Therefore,
Akm(s) =
{










with the appropriate and obvious definitions of (¯̀k−m, r̄k−m) and (¯̀k+m, r̄k+m). Thus, the set
Akm(s) is simply the set of all (`, r) such that 0 ≤ ` ≤ r ≤ N and with upper and lower
bounds on ` and r which get tighter as s increases.
Finally, in order to fully specify (PP(km)), we need to characterize Dkmj(a) = Dkmj(`, r).
Specifying Dkmj(`, r) as a function of continuous variables (`, r) will require an immense
amount of data. Instead, we use a common approximation obtained by discretizing each
MLC row into N beamlets (thus specifying an appropriate MLC row range), where beamlet
n represents the interval [n − 1, n]. We then precompute traditional beamlet-based dose
deposition coefficients Dkmnj, i.e., the dose rate to voxel j ∈ V from beamlet n in MLC row
m at control point k (n = 1, . . . , N , m = 1, . . . ,M , k = 1, . . . , K) at unit fluence rate and





where φkmj : [0, N ]→ R+ is the following step function:
φkmj(x) = Dkmnj, n− 1 < x ≤ n; n = 1, . . . , N.
Note that the coefficientDkmnj is similar, except in indexing, to the dose deposition coefficient
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dij defined in Section 1.2.2.











The problem (2.20) can be solved efficiently by noting that the only candidate values for `
and r that have to be considered are (i) integers, and (ii) the bounds derived from (2.19).
This is because function πkm(x; z̄) is monotonically increasing or decreasing for n− 1 < x ≤
n; n = 1, . . . , N , due to the structure of function φkmj(x).
2.7 From (MP) to (FP): gantry speeds and dose rates
Our column generation algorithm will return a feasible solution ȳ, z̄ and Āk, k = 1, . . . , K
to the problem (MP). As a final step of our solution procedure, we need to compute gantry
speed and dose rate vectors s and r consistent with this solution. Substituting the apertures





k = 1, . . . , K (2.21)
|sk − sk−1| ≤ ∆Sk k = 1, . . . , K − 1 (2.22)
sk ∈ [SL, SU ] k = 1, . . . , K (2.23)
rk ∈ [0, RU ] k = 1, . . . , K (2.24)
sk ≤ SUk−1,k(Āk−1, Āk) k = 1, . . . , K. (2.25)
This system has a feasible solution since the apertures and fluence rates computed by the
algorithm are guaranteed to be compatible with the gantry moving at speed SL. However,
this solution would lead to a treatment with undesirably long delivery time. Instead, we
33
would like to identify a solution to (2.21)–(2.25) that can be delivered in the shortest time
possible. Adding this objective function and rewriting constraints (2.21)–(2.25) in terms of







sk ∈ [SL, SUk ] k = 1, . . . , K








, k = 1, . . . , K.
If s̄k is an optimal solution to this problem, then the corresponding dose rates are r̄k = ȳks̄k,
k = 1, . . . , K.
In order to assess the impact on delivery time of the bound on the change in speed we will
also consider a relaxation of (SP) in which constraints (2.26) are removed. It is easy to see
that the corresponding solution will be to choose sk = S
U
k and rk = ȳkS
U
k (for k = 1, . . . , K).
2.8 Other considerations
In this section we discuss how additional constraints on the setting of the VMAT delivery
machine can be incorporated into the model (FP), its reformulation (MP), and our solution
heuristic.
2.8.1 Upper bound on fluence rate
Our basic model contained no bounds on the fluence rate, other than those implied by
bounds on the gantry speed and dose rate. An independent upper bound on the fluence rate
can be easily incorporated by including it among the constraints of (FP), and by calculating
Y U in (MP) and (RMP(C)) as the minimum of this upper bound and the ratio RU/SL.
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2.8.2 Lower bounds on fluence and dose rates
Our basic model did not include lower bounds on fluence and dose rates, other than
nonnegativity constraints. If such lower bounds Y L and RU , respectively, are dictated by
the VMAT delivery specification, they can be easily included among the constraints of (FP).
However, inclusion of one or both such bounds invalidates the reformulation steps that lead
to the equivalent problem (MP). We could then, instead, consider a generalization (MP)
in which we add lower bounds on the fluence which are the larger of Y L and RL/SU and
apply our heuristic solution procedure without modification (aside from the obvious addition
of lower bounds on fluence rates to (RMP(C))). The resulting mater problem, however, is
no longer equivalent to (FP), but rather is a relaxation. The consequences of using this
relaxation are:
(i) An intermediate solution obtained by solving (RMP(C)) with |C| < K may not be
extendable to a feasible solution to (FP). This means, in particular, that we have to
modify Step 2 of the greedy heuristic and add an aperture even if the optimal solution
value to the PP is nonpositive.
(ii) Postprocessing problem (SP) may not have a feasible solution. Therefore, we may have
to slightly modify the final treatment plan to be able to satisfy the constraints on the
rate of change in gantry speed.
2.8.3 Interdigitation and other MLC constraints
Lastly, consider a VMAT delivery system that does not allow interdigitation of MLC
leaves in adjacent rows. The main impact of this constraint is a modification of the solution
process of the pricing problem discussed in Section 2.6.2.
Before discussing the required modification, we will argue that if interdigitation con-
straints are satisfied in each iteration of the algorithm (i.e., for all apertures Āk, k ∈ C),
and we obtain a VMAT plan by linearly interpolating these apertures between control points
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in C, then the interdigitation constraints will also hold for MLC apertures throughout the
treatment. To obtain the interpolation, we assume that both the gantry and each of the
leaves move at constant speeds between two consecutive control points. Let us examine two
adjacent MLC rows m and m+ 1 at two control points k and k+. We assume that
¯̀
km ≤ r̄k,m+1 and ¯̀k+m ≤ r̄k+,m+1, (2.27)
i.e., the left leaf in row m and the right leaf in row m+1 do not overlap at either control point,
and denote the time it takes the gantry to rotate from k to k+ by ∆t. At an intermediate
time t ∈ (0,∆t), with the gantry at location c : k < c < k+, the leaf positions are computed
by linear interpolation as follows:




















It is easy to see that because of (2.27), we have `m ≤ rm+1; using the same technique we can
show that `m+1 ≤ rm, assuming same is true at control points k and k + 1. Thus, at any
location between the control points the interdigitation constraints are satisfied.
Now we study the impact of the interdigitation constraints on the pricing problem. Be-
cause of the dependency between individual MLC rows created by these constraints, we
cannot no longer decompose the problem (PP(k)) by row. As before, we characterize row
aperture am ∈ α at MLC row m of aperture A by (`m, rm) where 0 ≤ `m ≤ rm ≤ N and the
(integer) N represents the range of the MLC row, and denote by SUck(a
′
m, am) the maximum
gantry speed that will allow row m of aperture A = (a1, . . . , aM) at control point k to be
reached from row m of aperture A′ = (a′1, . . . , a
′
M) at control point c < k. To incorporate
the interdigitation constraints, we add the inequalities
`m ≤ min{rm+1, rm−1}, m = 1, . . . ,M (2.28)
to the description of the set Ac(s) in (2.16), where we let r0 = rM+1 =∞. By construction,
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Ak(s) 6= ∅ throughout the algorithm.









0 ≤ `m ≤ rm ≤ N m = 1, . . . ,M
|`m − ¯̀k−m|, |rm − r̄k−m| ≤
vδk−k
s
m = 1, . . . ,M (2.29)
|`m − ¯̀k+m|, |rm − r̄k+m| ≤
vδkk+
s
m = 1, . . . ,M (2.30)
`m ≤ min{rm+1, rm−1} m = 1, . . . ,M,
where Dkmj(`m, rm), as before, is approximated by an integral of the beamlet-based step
function φkmj : [0, N ]→ R+. Given this discretization of each MLC row into beamlets, this
version of the pricing problem can still be solved efficiently using a Dynamic Programming
approach described in Romeijn et al. (2005), with potential left and right leaf positions
including integers and bounds in (2.29) and (2.30).
2.8.4 Transmission effects
The leaves in the MLC system are designed to block all radiation directed at them.
However, since these leaves have finite hight, they cannot completely prevent the radiation
from passing. Transmission refers to the radiation dose leaked through individual leaves and
in between adjacent leaves in the MLC. Moreover, many MLC systems utilize leaves that have
round ends (Galvin et al. (1992)). Transmission effects are more serious in areas near the end
of leaves because of the smaller leaf hight. Boyer et al. (2001) provided recommendations
for MLC leaf design that require the leaves attenuate the beam to less than 5%.
Without explicitly taking transmission into account, the optimization dose will differ from
the actual delivered dose. In Appendix B we present a detailed derivation of the transmission
coefficient, α(τ1, τ2), for a beamlet that covers a segment that lies between τ1 and τ2, with
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τ1 < τ2, from the edge of the radiation field. With this information we can incorporate
transmission effects into the dose deposition coefficient for any aperture A ∈ A. Recall that




Dkmj(`km, rkm) ∀k = 1, . . . , K, j ∈ V .







α(`km − n− 1, `km − n)Dkmnj + α(0, `− b`kmc)(`km − b`kmc)Dkmb`kmcj
+ α(0, drkme − rkm) (drkme − rkm)Dkmbrkmcj +
N−1∑
n=drkme
α(n− rkm, n− rkm + 1)Dkmnj
 ,
where the un-attenuated dose deposition coefficients for partial beamlets [b`kmc, `km] and
[rkm, drkme] are approximated by the proportion of those of whole beamlets. We can use
coefficient Dkj(A) in the place of Dkj(A) to obtain a better approximation of the true co-
efficient. This can be done in both the restricted master problem and the pricing problem.
However, doing this in the pricing problem means that the solution is no longer guaranteed
to be either integers or the bounds derived from (2.19), and we may have to modify the so-
lution algorithm and find approximate solutions to the pricing problem. Therefore we only
take the transmission effects into account in (RMP(C)).
2.9 Data and implementation
Our algorithm was evaluated on a clinical dataset of prostate cancer patients treated at
UCSD Moores Cancer Center. The preprocessing steps, including image processing and cal-
culation of the dose deposition coefficients Dkmnj are performed using our in-house treatment
planning system. The dose calculations in this system are based on a finite-size pencil-beam
algorithm with 3-D density correction (Gu et al. (2009, 2011)). For each case we used beam-
lets of size 1 × 1 cm2 and voxels of size 4 × 4 × 2.5 mm3. The full voxel grid will be used
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in evaluating the dose distribution. However, in order to reduce the problem size, the op-
timization problem used a downsampled voxel grid that selected 1 of every 2 voxels along
each of the three dimensions in critical structures and 1 of every 4 in unspecified tissue. The
dimensions (after downsampling) and other characteristics of the 5 cases are summarized
in Table 2.1. Figure 2.2 illustrates the distribution of control points around the arc. For
all cases we used K = 177 control points, and the angular distances between control points
are shown in Table 2.1. Finally, the physical machine parameters we used are based on the
Varian VMAT machines (Varian Medical Systems, Inc., Palo Alto, CA, USA) and are shown
in Table 2.2 (where ∆Sk = ∆S for all k = 1, . . . , K).
Case # voxels # beamlets # Dkmnj 6= 0 δk (k = 3, . . . , 176) δ2, δ177 δ1










































Figure 2.2: Distribution of 177 control points around the arc for (a) Cases 1 — 4, and (b)
Case 5.
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RL RU SL SU ∆S v SAD SCD
(MU/sec) (MU/sec) (deg/sec) (deg/sec) (deg/sec) (cm/sec) (cm) (cm)
0 10 0.83 6.0 0.75 2.25 100 53.9
Table 2.2: Physical machine parameters.
The prescription dose to the PTV was set to 79.2 Gy, corresponding to a 44-fraction
treatment with 1.8 Gy delivered in each fraction. All Dose-Volume Histogram (DVH) based
criteria for the PTV and critical structures, in particular rectum, bladder, and femoral heads,
that were used to evaluate all treatment plans are based on clinical protocols at UCSD as
well as RTOG protocol H-0126 (Radiation Therapy Oncology Group (2004)) (see the ta-
bles in the remainder of this section for details). In our optimization model, we chose F
to be a voxel-based penalty function that penalizes the dose received by a voxel quadrat-
ically but asymmetrically with respect to a threshold dose that depends on the structure
containing the voxel; consequently, F is a smooth piece-wise quadratic convex function.
The structure-dependent relative weights of these penalty functions were determined using a
manual procedure that iteratively modified these weights until satisfactory treatment plans
were obtained for all 5 cases. This led to a common set of weights for all cases, thereby elim-
inating variation between cases caused by individual parameter tuning. In order to facilitate
the comparison between the treatment plans we normalized each treatment plan by scaling
the dose distribution so that 95% of the PTV receives the prescription dose.
Finally, we implemented our algorithm using the Compute Unified Device Architecture
(CUDA) to take advantage of the processing power of the Graphic Processing Unit (GPU).
GPU is a platform for implementation of large-scale parallelization of computer code, and has
been shown to be very suitable for solving radiation therapy treatment plan optimization
problem (Men et al. (2009, 2010a,b)). The RMP is solved using our in-house gradient
based solver. On an Nvidia Tesla C1060 GPU card, our algorithm takes 2 — 6.5 minutes
to complete. The high efficiency of our VMAT optimization engine provides a significant
step towards a clinical application of VMAT for adaptive radiotherapy, although of course
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a treatment planning system for adaptive radiotherapy would contain several additional
components.
2.10 Benchmark
Before evaluating our VMAT treatment plans, we provide a benchmark for comparison
by solving an IMRT treatment plan optimization problem with the same objective function
as (FP) and using the K = 177 beam angles that correspond to control points in the VMAT
treatment plan optimization model. These IMRT plans are used to assess the quality of
our VMAT plans and are not suitable for clinical use due to the unreasonably long time
required to deliver an IMRT plan with 177 beam angles. Since the IMRT treatment plan
optimization model allows intensity modulation at each beam angle and contains no con-
straints on aperture compatibility nor gantry speed, they can be viewed as an ideal, likely
clinically unattainable, solution. Therefore, any VMAT treatment plan that is close to this
ideal IMRT treatment plan will also be close to the optimal VMAT treatment plan.
Table 2.3 includes the clinical dose-volume criteria and the 177-beam IMRT plans eval-
uated with these criteria for all 5 cases. All plans are able to avoid significant hot- and
cold-spots in the PTV, and are able to satisfy most of the DVH criteria for the critical
structures. For Case 2 14% of the bladder volume and 18% of the rectum volume overlap
with the PTV, and for Case 4 almost 30% of the bladder volume overlaps with the PTV.
For these patients, even additional patient-dependent parameter tuning did not allow us to
resolve the violations highlighted in the table without introducing more serious ones.
2.11 Performance of VMAT plans
As discussed in Section 2.6.1, the column generation heuristic is parameterized by the
parameter s, which represents how “greedy” the heuristic is. Moreover, since the choice of
s affects the choice of Āk, which affects S
U
k in the time-minimization problem (SP), it also
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Structure Threshold Volume Case
Dose (Gy) Criterion (%) 1 2 3 4 5
PTV 73.7 ≥99 100 99 100 99 100
79.2 ≥95 95 95 95 95 95
87.1 ≤10 0 0 0 6 0
Rectum 75 ≤15 1 11 8 5 5
70 ≤25 2 13 11 8 6
65 ≤35 3 16 13 10 9
40 ≤45 12 26 24 28 20
Bladder 65 ≤17 5 20 13 42 10
40 ≤35 10 38 20 70 20
Femoral heads 50 ≤10 0/0 0/0 0/0 0/1 0/0
(L/R) 45 ≤25 0/0 0/0 0/0 0/3 0/0
40 ≤40 0/0 0/0 0/0 1/6 0/0
Table 2.3: Performance of 177-beam IMRT treatment plans.
impacts the delivery time of the final treatment plans. In this section we test our heuristic
under various settings of s, and study the performance of the resulting treatment plans in
terms of quality and delivery time.
2.11.1 The most greedy heuristic
Recall that a smaller value of s means that there are more apertures to choose from
in each iteration. We will start by choosing the smallest value of s, i.e., we will start by
investigating the most greedy variant of our heuristic. Note that we use the same objective
function as for the 177-beam IMRT optimization without any additional tuning, so that
the results only reflect the differences between the two modalities and treatment planning
techniques.
The results in Table 2.4 show that our VMAT treatment plans exhibit high quality in
general, closely resembling the IMRT treatment plans when evaluated with the same set
of clinical criteria. The major differences between the IMRT and VMAT plans are with
respect to the dose distribution in the femoral heads, but the VMAT plans still easily meet
all clinical criteria.
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Structure Threshold Volume Case
Dose (Gy) Criterion (%) 1 2 3 4 5
PTV 73.7 ≥99 100 100 100 99 100
79.2 ≥95 95 95 95 95 95
87.1 ≤10 0 0 0 1 1
Rectum 75 ≤15 2 11 8 4 5
70 ≤25 3 15 11 6 7
65 ≤35 4 17 14 9 10
40 ≤45 13 29 25 20 23
Bladder 65 ≤17 4 21 12 41 10
40 ≤35 11 39 21 66 19
Femoral heads 50 ≤10 0/0 0/0 0/0 0/0 0/0
(L/R) 45 ≤25 0/0 0/0 0/0 0/0 0/0
40 ≤40 0/0 0/0 0/0 1/0 0/0
Runtime (s) 284.9 323.8 271.4 223.9 299.0
Treatment time (s) 225.4 197.5 242.8 217.5 241.0
Table 2.4: Performance of VMAT treatment plans with s = SL = 0.83 deg/sec.
The second to last row of Table 2.4 contains the plan optimization times, in seconds,
using the algorithm for each case, while the last line shows the treatment delivery time for
each case. These treatment times range between 3.29 to just over 4 minutes, versus the
fastest allowable arc delivery time of 1 minute.
2.11.2 Effect of the value of s on treatment quality and time
Unfortunately, the treatment plans in Table 2.4 require relatively long treatment times,
which negates some of the benefits of using VMAT treatments. We therefore next study
whether we can choose a larger value of s, which can be expected to decrease treatment
time, without significant changes in treatment plan quality. In these tests we focus on Case
2, which is one of the more challenging cases.
Table 2.5 shows the performance of the VMAT treatment plans obtained for Case 2with
various values of s ranging from SL to SU . We can conclude that the treatment plan quality is
not sensitive to the choice of s. However, the overall treatment time is reduced dramatically,
by a factor of more than 1.3 from 3.3 minutes to just over 2 minutes, when using s = SU = 6.
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Finally, we provide an estimate of the total number of MUs required for treatment given by∑K
k=1 δk ȳk where the ȳk is the fluence rate at control point k in the final solution (see also
the definition of the fluence rates yk in Section 2.2). Note that even though the treatment
times for s = 4 and s = 6 are similar (slightly shorter with s = 4), a comparison of total
MU shows that using s = 6 is more desirable as the total MU required is much lower.
Structure Threshold Volume s (deg/sec)
Dose (Gy) Criterion (%) 0.83 2 4 6
PTV 73.7 ≥99 100 100 100 100
79.2 ≥95 95 95 95 95
87.1 ≤10 0 0 0 0
Rectum 75 ≤15 11 11 12 12
70 ≤25 15 14 15 15
65 ≤35 17 17 18 18
40 ≤45 29 29 32 32
Bladder 65 ≤17 21 21 22 21
40 ≤35 39 40 42 42
Femoral heads 50 ≤10 0/0 0/0 0/0 0/0
(L/R) 45 ≤25 0/0 0/0 0/0 0/0
40 ≤40 0/0 0/0 0/2 0/0
Runtime (s) 323.8 260.1 116.1 71.5
Treatment time (s) 197.5 171.8 145.8 149.3
Total MU 873.5 859.1 737.2 667.7
Table 2.5: Performance of VMAT treatment plans for Case 2 obtained with different s values.
2.11.3 Least greedy heuristic
Based on the results in the previous section we focus our further analysis on the least
greedy heuristic. Table 2.6 shows the performance of the VMAT treatment plans obtained
with s = SU = 6. Similarly to Case 2 we conclude that there is no significant changes
clinically in treatment plan quality as compared to the plans in Table 2.4, but the treatment
time is greatly reduced for all cases. In particular, the treatment time is consistently just
over 2 minutes for all 5 cases.
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Structure Threshold Volume Case
Dose (Gy) Criterion (%) 1 2 3 4 5
PTV 73.7 ≥99 100 100 100 99 100
79.2 ≥95 95 95 95 95 95
87.1 ≤10 0 0 0 2 0
Rectum 75 ≤15 1 12 9 4 5
70 ≤25 3 15 13 6 8
65 ≤35 4 18 16 9 10
40 ≤45 18 32 31 27 28
Bladder 65 ≤17 5 21 13 43 11
40 ≤35 12 42 24 71 22
Femoral heads 50 ≤10 0/0 0/0 0/0 0/1 0/0
(L/R) 45 ≤25 0/1 0/0 1/2 1/4 0/0
40 ≤40 0/4 0/0 5/5 4/6 3/1
Runtime (s) 78.8 71.5 59.2 54.2 67.6
Treatment time (s) 149.3 149.3 141.1 142.6 155.5
Total MU 611.5 667.7 539.0 557.6 610.4
Table 2.6: Performance of VMAT treatment plans with s = SU .
2.11.4 VMAT treatment plan quality compared to benchmark
Figure 2.3 shows the DVHs of the 177-beam IMRT and VMAT (with s = SU = 6)
treatment plans for Cases 1 — 5. As can be gleaned from the corresponding tables, the
largest differences in these plans are with respect to the dose distribution in the femoral
heads, but these are still well within the clinical protocol. Given the restrictions that VMAT
delivery imposes on a treatment plan, we feel that the quality of the VMAT plan is not only
clinically acceptable, but also high since the degradation from the idealized 177-beam IMRT
plan is relatively small.
2.11.4.1 Disallowing interdigitation
In order to study the effect of using an MLC system that does not allow interdigitation,
we implemented the modified pricing problem (PPI) described in Section 2.8.3 and applied
our resulting algorithm on all 5 cases. Our experiments revealed no significant change in














































































































































Figure 2.3: DVH comparison for Cases 1 — 5. Solid: 177-beam IMRT; dashed: VMAT
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increased complexity of the pricing problem (see Table 2.7).
Solution time (s) Case
1 2 3 4 5
Allowing interdigitation 78.8 71.5 59.2 54.2 67.6
Disallowing interdigitation 511.5 351.7 685.3 300.1 660.5
Table 2.7: Impact of disallowing interdigitation on algorithm run time.
2.11.5 Rate of change in gantry speed
Now we investigate the effect of the constraint on the rate of change in gantry speed on
treatment time. As discussed in Section 2.7, we can assess the impact of the rate of change
restriction by removing the corresponding constraint (2.26) from problem (SP). As before,
we focus this study on Case 2.
Figure 2.4 plots the gantry speeds and dose rates for control points 1 through 176 for Case
2. Graphs (a-1) and (b-1) show gantry speeds, and (a-2) and (b-2) show dose rates, obtained
by setting s = SU = 6 in the column-generation algorithm, with rate of change constraint
(2.26) omitted for graph (a-1) and (a-2), but included for graph (b-1) and (b-2). Graphs
(c-1) — (d-2) contain analogous results with s = 4. It is clear that without a constraint on
the rate of change, the gantry speed changes rapidly during the treatment in order to extend
the time spent at apparently favorable control points while limiting the time spent at less
favorable ones. Notice as well that at most control points the speed remains equal to the
value s used in the column generation algorithm even after solving (SP).
When the rate of change constraint is enforced, as in parts (a-1) and (c-1), the sequence
of speeds is smoothed so that the change in speed between control points is no more than
∆Sk. Note that, as discussed in Section 2.7, the rate of change constraint does not have any
impact on treatment plan quality. However, if it were technologically feasible to increase
or eliminate the bound on the rate of change in gantry speed, the treatment time could be
shortened by about 35% to 1.7 minutes, as shown in Table 2.8.
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Figure 2.4: Gantry speeds (left column) and dose rates (right column) vs. control points for
Case 2: (a) s = 6 deg/sec, ignoring rate of change constraint; (b) s = 6 deg/sec, considering
rate of change constraints; (c) s = 4 deg/sec, ignoring rate of change constraint; (d) s = 4
deg/sec, considering rate of change constraints.
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Treatment time (s) Case
1 2 3 4 5
Without bound 97.8 99.4 91.6 94.9 98.9
With bound 149.3 149.3 141.1 142.6 155.5
Table 2.8: Impact of the presence of the bound ∆S on the rate of change in gantry speed
on treatment time.
2.11.6 Transmission dose
Finally we study the effect of incorporating the transmission dose into the dose calculation
during the optimization process. Again we incorporate the transmission dose by using the
modified coefficient Dkj(A), explained in Section 2.8.4 in the (RMPC). We first examine the
impact of transmission on the dose distribution by applying the plan generated for Case 2
with S = SU , and calculating the delivered dose with and without transmission. Figure 2.5
(a) shows a comparison of the DVH curves obtained in these two different settings. Because of
transmission dose, the delivered dose is higher for all of the structures. However, the shapes of
the corresponding curves remain similar. Normalizing the final dose distributions, for which
the dose is scaled down 6.5%, reveals that given the same target coverage, transmission dose
adds slightly to the dose to critical structures and normal tissues.
As discussed in Section 2.8.4, considering transmission helps us find better solutions to
the (RMP(C)), which lead to more accurate aperture prices in (PP(k)) and better apertures
being added in the column generation process. We compare two solutions, one obtained with
transmission taken into account in the optimization process, and one without. For each plan
we include transmission dose in calculating the the final dose distribution. The results can
be seen in Figure 2.5 (c). Being able to incorporate the transmission dose in the optimization
problem results in slightly lower doses to the critical structures and more homogeneous dose
in the target. Moreover, the delivery time, MU and optimization time are all similar to the






















































































Figure 2.5: Case 2 s = 6, (a): final dose with (dashed) and without (solid) transmission; (b):
final dose with (dashed) and without (solid) transmission, where transmission dose normal-
ized to 95% target coverage; (c): normalized final dose with transmission, plan optimization
with (dashed) and without (solid) considering transmission
Optimization scheme runtime (s) treatment time (s) total MU
With transmission 85.8 143.1 665.4
Without transmission 71.5 149.3 667.7




We have developed an efficient algorithm for generating VMAT treatment plans. Our
approach incorporates various physical constraints, including bounds on dose rate, gantry
speed, and rate of change in the gantry speed during treatment. Moreover, the approach is
flexible enough to allow for additional constraints, including MLC delivery constraints. We
have shown that our algorithm is capable of generating treatment plans of high quality on
5 prostate cancer cases. The VMAT plans produced by our algorithm can be delivered in
around 2 minutes. Moreover, a GPU implementation allows us to complete the optimization
within a couple minutes. Along with additional 15 seconds for computing the dose deposition
coefficients before the optimization and 15 seconds for computing the final dose distribution
after the optimization using a GPU-based dose calculation engine (Gu et al. (2011, 2009)),




VMAT with Constant Gantry Speed and Dose Rate
3.1 Introduction
Volumetric Modulated Arc Therapy (VMAT) with constant gantry speed and dose rate
(VMATC) was first introduced in its initial form in Yu (1995) as the Intensity Modulated
Arc Therapy (IMAT). In this type of treatment, the gantry rotates continuously around the
patient while the radiation source is tuned on. The leaves in the Multileaf Collimator (MLC)
system move dynamically to modulate the shape of the exposed field (aperture), however,
both the gantry speed and the source output rate (dose rate) must stay constant during the
treatment.
VMATC treatment has attracted the attention from many researchers as well as clini-
cians. Similar to VMAT, VMATC treatment is delivered while the gantry is in continuous
motion, whereas the conventional Intensity Modulated Radiation Therapy (IMRT) delivers
radiation sequentially from a number of beam angles in a “step-and-shoot” fashion, and
requires setup time between consecutive beam angles. Moreover, IMRT delivery from each
beam angle takes a long time because of the intensity modulation required. As a result,
VMATC has the potential to shorten the overall treatment time compared to IMRT, which
leads to less patient discomfort, less intrafraction motion uncertainties, as well as increased
equipment utilization for the clinics. Furthermore, VMATC is able to use a large set of angles
around the patient, instead of being restricted to a relatively small number of pre-determined
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angles. This may potentially lead to improved treatment plan quality over IMRT.
VMATC treatments can be delivered from an IMRT treatment machine equipped with
conventional linear accelerator and MLC system. Because IMRT is commonly used as the
primary external beam radiation therapy treatment method, this gives a wide range of clinics
access to research and experiments with VMATC treatments. However, VMATC lacks the
flexibility to dynamically vary the gantry speed and dose rate. This gives the optimization
for VMATC a very different nature from that for VMAT. Therefore it is necessary to develop
optimization algorithms specifically for VMATC.
Because of the lack of inverse planning techniques, some early efforts in designing treat-
ment plans for VMATC were focused on using a Beam-Eye-View (BEV) approach, by align-
ing the apertures at different angles to the shape of the projected target (Yu et al. (2002);
Wong et al. (2002)). The majority of research was done by converting IMRT plans and
making them deliverable in treatments consisting of multiple arcs. Yu (1995) relied on an
IMRT treatment with beams 5◦ apart as the starting plan. The intensity profile at every
beam was then heuristically decomposed into a number of intensity levels and the associated
leaf positions, so that the leaf positions with matching intensity level at different angles are
compatible on the same arc. Crooks et al. (2003) segmented an IMRT fluence map at each
angle into several intensity levels, and distributed these segments on the small arc between
two consecutive angles. The time it takes for the gantry to traverse this arc is divided
and assigned to each segment so that their delivery time, and thus intensity, matched the
original intensity. However, the authors assumed that segment transition can happen instan-
taneously, and that the leaf travel speed was unbounded, which may lead to undeliverable
plans. Moreover, the gantry speed necessary to deliver the treatment may be undesirably
slow in the solution. In a study on designing leaf-sequencing methods for converting IMRT
fluence map to deliverable leaf settings, Shepard et al. (2007) employed a simulated anneal-
ing heuristic to find the leaf settings that best resemble the IMRT fluence map. Later in a
similar study, Luan et al. (2008) applied a shortest path algorithm that minimizes the error
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between the original IMRT and the sequenced fluence maps. However, due to the differences
between IMRT and VMATC treatments, a treatment plan designed for IMRT and perturbed
to satisfy the compatibility constraints is not necessarily a good plan for VMATC. More-
over, the process of converting the IMRT plan will inevitably introduce degradations in plan
quality, and the commonly used method of minimizing the difference in fluence maps may
not lead to the minimal difference in plan quality.
Using heuristic methods that do not depend on a prior IMRT treatment plan, Cotrutz
et al. (2000) proposed an approach that combined a number of arcs, each with a manually
picked rectangular aperture, to produce a treatment. Earl et al. (2003) and Cameron (2005)
both proposed methods that used simulated annealing to perturb the starting set of aper-
tures, which conformed to the shape of the projected target at different angles (i.e., a BEV
approach). In the former article the dose rate was part of the decisions perturbed in the
simulated annealing method, whereas in the latter two the dose rate was determined through
optimization for the given leaf positions.
The results in these studies showed that either multiple arcs or one arc with long delivery
time were required to generate VMATC treatment plans that resemble the quality of a
conventional IMRT plan. In favor of this observation, Bortfeld and Webb (2009) performed
a theoretical study based on a phantom case, and claimed that single-arc VMATC plans
may unduly compromise the plan quality compared to IMRT plans if the treatment time
was to be kept under 2 minutes.
The above-mentioned studies, among others, have lead to the advancement in treat-
ment technologies and the introduction of dedicated commercial VMAT systems that enable
variable gantry speed and dose rate during the treatment, and research focus has shifted
towards plan optimization problem for full VMAT treatments since (Otto (2008); Bedford
(2009); Men et al. (2010b); Peng et al. (2012)).
Although VMATC lacks two important features, namely dynamically changing gantry
speed and dose rate during the treatment, being able to deliver this type of treatment can
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still be very appealing to clinics equipped with conventional IMRT machines, as VMATC
treatment provides many the benefits of full VMAT without requiring an expensive system
upgrade. This can be particularly beneficial to countries that do not have access to treatment
machines with full VMAT capabilities. Moreover, fully realizing the potential of VMATC
treatment will require investigation into all degrees of freedom it offers. To the best of
our knowledge, none of the existing research studies on VMATC have directly taken the
optimization of the constant gantry speed into account. However, as gantry speed directly
determines how far the leaves can travel between consecutive control points and thus the
allowed change in aperture shapes, it impacts the plan quality in addition to treatment time.
In this research we consider the treatment planning problem for VMATC with a single
arc, and we treat both (constant) gantry speed and dose rate as decision variables in the
optimization process. We compare our VMATC plans with VMAT on actual patient cases,
and show that VMATC can generate single-arc treatment plans with quality close to full
VMAT. Our approach can readily be extended to treatments with multiple arcs. The results
of our research may help clinics make an informed decision when upgrading to dedicated
VMAT systems.
3.2 VMATC optimization problem formulation
We assume that during VMATC treatment the gantry rotates continuously along a pre-
specified trajectory. Let S denote the constant gantry speed, chosen from a range [SL, SU ]
that is physically feasible for the treatment machine, and let R ∈ [RL, RU ] represent the
constant dose rate for the VMATC treatment. The MLC apertures can, in principle, be
controlled at every angle on the gantry rotation trajectory. However, for tractability reasons
the treatment is usually defined by controlling the apertures at all or a subset of K discrete
control points along the arc. We define the angular distance between control point k − 1
and k as δk (k = 1, . . . , K), and define an additional control point 0 in the beginning of
the treatment arc for convenience. In between control points, the treatment machine will
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configure itself so that the leaves in the MLC move at constant speeds to reach their positions
at the next control point from the previous control point.
By controlling the machine this way, we can in principle calculate the dose to each voxel
as a function of S, R, and the leaf positions along the gantry trajectory. However, computing
the dose based on the continuous leaf motion is not only inefficient, but also impractical,
since it usually needs to be done numerous times in the optimization process. We therefore
consider an approximation that computes the overall dose as the sum of dose associated with
the control points. Note that this is the same “step-and-shoot” approximation described in
Chapter II, which assumes that the aperture stays constant on the arc spanning control








∀j ∈ V , (3.1)
where Dkj(Ak) is the dose deposition coefficient associated with aperture Ak and voxel j,
and Rδk
S
equals the total source output (measured by Monitor Unit (MU)) delivered from
control point k. Otto (2008) showed that zj calculated by (3.1) will be sufficiently close to
the actual dose if K is sufficiently large and δk is sufficiently small for all k ∈ {1, . . . , K}.
Now given that the VMATC planning problem is essentially a VMAT problem with
variables S and R restricted to be constant for all angles, we can easily modify formulation












j ∈ V (3.2)
S ≤ SUk−1,k(Ak−1, Ak) k = 1, . . . , K (3.3)
S ∈ [SL, SU ]
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R ∈ [RL, RU ]
Ak ∈ A k = 1, . . . , K.
Recall that SUk−1,k(Ak−1, Ak) is the maximum speed allowed for the MLC apertures to shift
from Ak−1 to Ak between control points k−1 and k, and A is the set of apertures deliverable
by the MLC system.
Although this problem appears similar to problem (FP), it cannot be solved using the
same algorithm, where after every aperture is added to the master problem, the fluence rates
of all apertures need to be chosen so that the objective function value will improve. For the
VMATC problem, the fluence rate must always be the constant value associated with S and
R. As a result, adding an aperture with a negative price may actually lead to a worsened
objective function value. Therefore, we will develop (heuristic) algorithms specifically for
(VC) in this chapter.
3.3 Decomposition approaches to (VC)
Solving (VC) directly is difficult; in what follows, we propose and test two heuristic
optimization frameworks that rely on the decomposition approaches to (VC) described in
this section. Problem (VC) has two types of decisions: (i) selecting values of continuous
variables S and R, and (ii) selecting apertures at control points. To describe our heuristic
optimization frameworks, it is convenient to consider the following two “decomposition-
based” interpretation of (VC).
3.3.1 Decomposition approach 1: gantry speed and dose rate selection as a
sub-problem
Suppose that we have selected one aperture Ak for every control point k ∈ {1, . . . , K},
then the gantry speed and dose rate can be optimized. However, not all gantry speeds in
the range [SL, SU ] can be used, as S must be compatible with the apertures in consecutive
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control points in order to allow the current aperture sequence to be deliverable. Let M be
the set of MLC leaf rows, and let akm = (`km, rkm) be the leaf setting in row m ∈ M at
control point k. Finally, let v be the maximum travel speed for leaves in the MLC. It can










∀m ∈M, k ∈ {1, . . . , K}. (3.5)
These conditions ensure the gantry rotation time between two consecutive control points is
sufficient for the leaf transition. We can define the maximum allowed (constant) speed S̄U























R ∈ [RL, RU ] (3.6)
S ∈ [SL, S̄U ]. (3.7)
As long as S̄U , SL > 0, which is apparent as the gantry must rotate at a positive speed,
this problem can be transformed into an equivalent optimization problem by defining fluence
rate y = R
S








Dkj(Ak) δk y ∀j ∈ V
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Note that problem (DY(A)) is a convex problem that can be easily solved.
3.3.2 Decomposition approach 2: aperture selection as a sub-problem
The gantry speed, together with the fixed maximum leaf travel speed, determines how
far individual leaves in the MLC can travel between two control points, which in turn de-
termines the sequence of apertures deliverable in the treatment. Once the gantry speed and
dose rate combination is chosen, the achievable plan quality only depends on the aperture
selection (i.e., leaf setting) at each control point. We formulate the problem for optimizing
the apertures as follows:











S ≤ SUk−1,k(Ak−1, Ak) k = 1, . . . , K
Ak ∈ A k = 1, . . . , K.
We observe that solving (VC) is the same as minimizing H(S,R) over S and R, or





S ∈ [SL, SU ] (3.8)
R ∈ [RL, RU ]. (3.9)
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However, directly solving (LS(S,R)) is difficult, as the dose deposition matrix Dkj(Ak) has
a complex relationship with Ak that is dependent on the patient’s anatomy. We describe a
heuristic method for solving this problem in the next section.
3.4 Methods for (approximately) solving (LS(S,R))
We propose an algorithm for solving (LS(S,R)) that iteratively selects and refines apertures
at the set of control points, while maintaining a deliverable treatment plan throughout the
solution process. We start with an outline of the algorithm:
1. Initializate with an “empty” treatment – all apertures are assumed “closed”. Let C = ∅
be the set of control points that currently have apertures selected
2. Selecting an initial sequence of apertures:
(a) determine a sequence of control points, which we will follow to select the apertures;
(b) for the next control point in the sequence, say k̄, set C ← C ∪{k̄}, select aperture
Ak̄;
(c) if |C| = K, go to Step 3; otherwise go to Step 2(b).
3. Refining the collection of apertures selected in Step 2:
(a) determine a sequence of control points to follow;
(b) perform the following refinement step:
i. for the next control point in the sequence, say k̄, refine aperture Ak̄;
ii. if we are at the end of the sequence, go to Step 3(c); otherwise go to i.
(c) terminate if the objective does not improve; otherwise repeat Step 3(b).
In this algorithm, every time an aperture is selected or refined, it is done in a way that
will improve or maintain the quality of the current solution. We discuss this in detail in the
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following sections. In our implementation in Section 3.6, we used the following sequence of
control point in both Steps 2 and 3: the first two apertures are selected at control points
1 and K, the next aperture is selected halfway between 1 and K to reduce the distance
between selected apertures by half, then two more apertures are selected to reduce the
distance between selected apertures to 1/4 or the entire arc, etc., until all the control points
have apertures selected.
3.4.1 Determining apertures at all control points given set C
Recall that when an aperture is selected at every control point and S and R are given,
the same “step-and-shoot” approximation we used for VMAT can be used to perform the
dose calculation. However, during Step 2 of algorithms that fit the above general description,
we will encounter intermediate steps in which only a subset of the control points have an
aperture specified. Unlike in VMAT, where we would set dose rate at such control points to
zero, varying the dose rate is not an option in VMATC if we want to maintain a deliverable
plan at every step of the algorithm, and care needs to be taken when calculating the delivered
dose in this situation.
Let C ⊂ {1, . . . , K} be the subset of control points that have apertures specified in the so-
lution process. Then the apertures at all other angles, including control points {1, . . . , K}\C,
can be found by linearly interpolating the leaf positions at control points in C. We can de-
fine function F , which calculates leaf settings amk at control point k ∈ {1, . . . , K} and row
m ∈M , given those specified in C:


















Here k− and k+ are the indices of control points in C that are immediately before and after
control point k, respectively:
k− = max{c, c ∈ C : c ≤ k} and k+ = min{c, c ∈ C : c ≥ k}
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It is easy to see that k−, k+ and k coincide if k is itself included in C.
In the discussion so far we assumed that we used at least two control points 1 and K.
Under this assumption, the control points k− and k+ are well-defined for any k ∈ {1, . . . , K},
allowing us to evaluate F via a simple interpolation. However, we can extend the definition
of function F to cover other situations: if control point k has no aperture specified before
(after) itself, it will use the same aperture as the one specified at the control point after
(before). And if no aperture has been specified yet, it is natural to define the treatment
plan as empty where all leaves are closed at the edge of the beam. Once the apertures at all
control points are determined with function F , we can readily calculate the dose distribution
using (3.1).
3.4.2 Methods for selecting/refining apertures
In Steps 2 and 3 of the aperture selection algorithm, we select apertures sequentially at
the set of control points so that the treatment quality can be improved. In this section we
describe two types of methods, one based on a local search procedure that can only examine
a finite set of options when selecting the leaf setting, the other based on optimization, which
can find the leaf setting in one row optimally but takes longer to execute. Moreover, the
optimization based method can only be applied in refining the apertures.
3.4.2.1 Local search heuristic
This method can be used in both Steps 2 and 3 of the above algorithm. Suppose that
the set of control points that currently have an aperture selected is C ⊂ {1, . . . , K}, and
now for more control over the treatment delivery process and/or for improving the solution
quality, we want to increase the number of selected apertures by 1, say at k ∈ {1, . . . , K}\C.
The leaves at k used to occupy the interpolated positions determined by the selected control
points k− and k+ in C. To choose a potentially better leaf setting, first we need to determine
which ones are feasible in each row. This is again dictated by the constant gantry speed and
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the leaf travel speed:




















`mk ≤ rmk (3.15)
Here (3.15) is the physical restriction that leaves in the same row cannot overlap. Note that
these restrictions are written assuming k− and k+ both exist. If either or none of them exist
because control point k does not have a preceding or succeeding control point, we can simply






(m ∈ M), be the original interpolated leaf positions at k. Con-
straints (3.11) — (3.14) provide a feasible range, say [`m,
¯̀
m] and [rm, r̄m], for the left and
the right leaves (`mk, rmk) in each row m ∈ M . Suppose that the dimension of each row
is [0, N ], and we divide it into N beamlets along the leaf travel direction in order to allow
computation of the dose deposition coefficients in a pre-processing step. We propose the
following method for selecting/refining the aperture at k:






2. for each row m ∈M sequentially, perform the following local search:




: ˆ̀mk ≤ r̂mk, ˆ̀mk ∈ {`m, d`me, . . . , b¯̀mc, ¯̀m, ˜̀mk},
r̂mk ∈ {rm, drme, . . . , br̄mc, r̄m, r̃mk}}





(b) find the interpolated leaf positions in row m ∈M for control points k−, . . . , k− 1
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and k + 1 . . . , k+ using (3.10)
(c) calculate the corresponding dose distribution using (3.1), and evaluate the objec-
tive function
set (`mk, rmk) to be the leaf setting that provides the minimum objective.
The leaf position in any beam row found in this procedure will either be the original
interpolated position, a boundary point, or one that occupies one of the beamlet edges. This
ensures that the treatment plan quality can be improved or maintained after an aperture is
selected/refined.
3.4.2.2 Exact optimization
This is an alternative method for refining the aperture selection in Step 3 of the algorithm
above, and is based on identifying the feasible ranges for leaf positions in each row given S and
the apertures currently selected at k− 1 and k+ 1, and partitioning those ranges into small,
usually beamlet-sized intervals. Within each interval, the dose vector is an affine function
of the leaf position, and thus the optimal leaf positions within that interval can be obtained
by solving a continuous optimization problem. By enumerating all such intervals, we can
obtain an optimal leaf setting (for given S and R, and apertures selected at other control
points). However, the solution time of all of these optimization problems will significantly
exceed that of the local search heuristic presented above. We will study the tradeoffs between
solution quality and running time of the two aperture selection methods. Moreover, we will
only utilize this method in Step 3 of the algorithm, when k− = k − 1 and k+ = k + 1, since
otherwise changing the leaf positions at k affects all control points between k− and k+, and
the number of intervals we need to consider may be too large to execute the procedure.
Assuming all control points k ∈ {1, . . . , K} has one aperture assigned already, we study
the optimization of leaf settings at control point k̄ ∈ {1, . . . , K} and row m̄ ∈M . Note that
dose delivered from all other control points is constant, and that dose delivered from rows
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∀ j ∈ V .
Here Dkmj(amk) is the dose deposition coefficient associated with the leaf setting amk at
control point k, row m, and voxel j. Suppose that the left and right leaf positions in row m̄









` ∈ [`, ¯̀], r ∈ [r, r̄], 0 ≤ ` ≤ r ≤ N (3.17)
Again we use [`, ¯̀] and [r, r̄] to represent the feasible ranges for the left and the right leaves
derived from constraints (3.11) — (3.14).
Recall that we discretize a continuous beam row into N different beamlets. In order to
compute the dose deposition coefficient associated with leaf setting (`, r), we assume that a
partially covered beamlet will deliver dose proportional to the fraction of the beamlet area
that is exposed. As a result this coefficient coefficient can be computed as:
Dk̄m̄j(`, r) =









where Dkmnj is the beamlet-based dose deposition coefficient associated with beamlet n in
row m at control point k.
Both terms in (3.18) are piece-wise linear and neither convex nor concave in general,
therefore problem (LO) is not directly solvable. However, when ` and r are each restricted
to be within a beamlet, problem (LO) is convex. We can then independently solve (LO) for
every combination of intervals:
` ∈ [`, d`e], or [d`e, d`e+ 1], . . . , or [b¯̀c, ¯̀], and
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r ∈ [r, dre], or [dre, dre+ 1], . . . , or [br̄c, r̄],
for which ` ≤ r is satisfied. The solution to the optimization problem that yields the best
objective function value is then the optimal solution to (LO).
3.5 Two frameworks for finding (approximate) solutions to (VC)
With the technical preliminaries explained, we are ready to describe the two frameworks
for solving problem (VC).
3.5.1 Framework A: approximately solving (SR)
Recall that if we solve problem (SR) to optimality, we will have the optimal solution
to (VC). However, the methods for evaluating the objective function of (SR) by solving
(LS(S,R)) described in Section 3.4 are heuristics, and thus solving (LS(S,R)) only yields an
approximate solution. Let H̃(S,R) be the objective value obtained by applying a heuristic





subject to (3.8) and (3.9). Note that one single evaluation of function H̃(S,R) is equiva-
lent to performing the entire aperture selection procedure, and therefore is computationally
expensive. As a result, performing a large number of function evaluations is not realistic.
Moreover, the fact that we solve problem (LS(S,R)) with a heuristic method means that
H̃(S,R) does not provide any reliable information about the smoothness, differentiability or
convexity of H(S,R). Therefore we have to solve problem (SRapprox) with a method that
does not rely on derivatives. Optimization algorithms of this type usually fall into one of
the following categories:
1. Line-search methods based on estimated gradients. This type of method estimates
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the gradient value with approximation techniques, such as finite differences (Gilmore
and Kelley (1995)), then performs a line search along a direction dependent on the
gradient to find a improving solution. However, in cases when the objective function
is not smooth or continuous, the approximated descent direction is not necessarily
a good direction to search along. Moreover, finding the step size may involve many
function evaluations, making it unattractive for expensive functions like ours (Fowler
et al. (2008)).
2. Search heuristics that mimic processes and phenomenon that happen in nature, such
as simulated annealing and genetic algorithm. Simulated annealing (Kirkpatrick et al.
(1983); Van Laarhoven and Aarts (1987)) models the annealing process in metallurgy.
In each step the algorithm probabilistically determines if it will move to a neighboring
point of the current point, and the probability that controls this process is dynamically
and usually slowly changed to lead the system to points with better objective func-
tion values. Genetic algorithm as well as related heuristics (see, for example, Goldberg
(1989); Gen and Cheng (1999)), mimics the natural evolution process. It maintains a
population of solutions, and by selecting, mutating and varying stochastically individu-
als that are more fit, i.e., have better objective values, produces a new population from
the current one. These algorithms have performed very well in finding good (but not
necessarily optimal) solutions in practice. However, the optimization process usually
requires a large number of function evaluations.
3. Direct search algorithms. This includes a family of pattern search methods (Audet and
Dennis Jr (2004); Conn et al. (2009)), and simplicial search methods, (most notably
the Nelder-Mead algorithm Nelder and Mead (1965)), among others. These methods
decide where the next function evaluation will take place entirely based on the function
values encountered in history. These methods, especially the Nelder-Mead method,
have been popular among scientists faced with an expensive function and a limited
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computational budget because of their ability to find good solutions within a relatively
small number of function evaluations (Lagarias et al. (1998)).
4. Trust region based methods. These methods rely on approximating the objective func-
tion with analytical and usually quadratic functions (a.k.a. a surrogate model) that are
easy to evaluate and optimize. By maintaining a trust region, in which the surrogate
model is believed to be a good approximation of the underling function, and optimizing
the surrogate model over the trust region, the algorithm proceeds to new solutions be-
lieved to provide sufficient decrease for the underlying function. The surrogate model
and the trust region are continuously modified as the algorithm proceeds. These meth-
ods are attractive because the quadratic surrogate models used make them very robust
when dealing with curvature information. Extensive research has been done to inves-
tigate the convergence properties and application of these methods (Conn et al. (2000,
2009)).
5. Response surface methods (RSM). RSM is a collection of methodologies useful in appli-
cations such as optimization, and selection of conditions to meet requirements (Mont-
gomery and Myers (2002)). The fact that RSM can fulfill the users’ goals by using a
limited number of observations makes it a desirable choice for many. RSM assumes
the underlying function of interest is noisy because of an underlying statistical error
component, and is usually based on an approximation of the function by a low order
polynomial. Optimization with RSM in general involves an iterative process of fitting
a model to available data, finding improving directions, moving along the direction to
a new solution, and updating the model.
Although many of these methods and/or their variants, with the exception of those
in the second category, have been shown to converge locally or globally for continuously
differentiable functions (see, for example, Lagarias et al. (1998); Conn et al. (2009)), in cases
when no information is available about the objective function, none of these methods can
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guarantee convergence even to locally optimal solutions. Moreover, given that the evaluation
of function H̃(S,R) is likely to take a nontrivial amount of time, it is highly desirable that
we chose a method that can efficiently reduce the objective function in small number of
iterations, and one that can work with function shapes that do not necessarily resemble
linear or quadratic functions. For these reasons, we choose the Nelder-Mead algorithm to
apply in our experiments.
We give a brief introduction of the Nelder-Mead method following the notations in Conn
et al. (2009). For an optimization problem in n-dimensions, the Nelder-Mead algorithm
is based on maintaining and changing a simplex of n + 1 vertices Y = {y0, . . . , yn}. The
method iteratively replaces the worst vertex, say yn, from the simplex with a point on the
line connecting yn and the centroid of the best n vertices yc. The new vertex of each iteration
can be one of the following types (illustrated in Figure 3.1 (a)): a direct reflection yr, an
expansion ye, an outside contraction yoc, or an inside contraction yic. However, in some
cases the algorithm can perform a shrink, which only keeps the best vertex, and shrinks the
simplex by moving all other vertices close to the best one (illustrated in Figure 3.1 (b)).
In each iteration, the algorithm first evaluates objective value at yr, then potentially at ye,
yoc, yoc or yic. The type of outcome is determined by the objective values at these points
relative to the objective value of the n+1 vertices in the current simplex. The algorithm can
be terminated when the diameter of the simplex reduces below a predetermined threshold,
or when the difference between the minimum and maximum objective values at all vertices
becomes smaller than a threshold, or alternatively, as the original authors suggested in Nelder
and Mead (1965), when the variance in the objective function values at all vertices drops
below certain threshold, at which point the best vertex in the final simplex is used as the
solution. In the experiments we use a modification of the implementation in the NLopt




Figure 3.1: Possible outcomes of one Nelder-Mead iteration, starting from initial simplex
{y0, y1, y2}
3.5.2 Framework B: alternating optimization
An alternative framework for solving (VC) is by using an alternating optimization (AO)
scheme. The AO method, sometimes also referred to as the Gauss-Seidel method (), is
suitable for situations where the problem is difficult to solve directly, and there is a natural
partitioning of variables for which the optimization is easy to carry out for each group of
variables. The problem is then solved by alternating among each subset of variables. Our
second framework, illustrated in Figure 3.2, is as follows:
1. Generate an initial (S,R) pair, solve problem (LS(S,R)) to obtain a set of apertures.
2. Given the apertures, optimize the gantry speed and dose rate by solving problem
(GD(A)) described in Section 3.3.1.
3. If the objective function value does not improve, terminate; otherwise update gantry
speed and dose rate and go to Step 4.
4. Refine the apertures given the updated (S,R) pair until no more objective improve-
ments can be made; go to Step 2.
Note that the solution to problem (GD(A)) will provide us with an optimal fluence rate
y∗. However, there may be multiple (S,R) combinations that correspond to this ratio and
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Figure 3.2: Optimization scheme for VMATC treatment plans
satisfy (3.6) and (3.7). Although it is not apparent which (S,R) pair will lead to better final
solutions, selecting a slower gantry speed will inevitably result in longer treatment times.
Moreover, the aperture selection procedure will take advantage of a slower gantry speed,
and allow the MLC leaves to travel longer distances between two control points. This will
in turn lead to smaller S̄U value the next time we solve problem (GD(A)). As a result, from
an initial (S,R) pair, treatment plans generated later in framework B will have the same
or longer treatment times than those seen earlier. This can be mitigated by choosing the
resulting (S,R) values in such a way that the treatment time is minimized, in other words,
choose values:










Under conditions on the differentiability and/or the convexity of the objective function,
and the feasible set being a Cartesian product of sets, global convergence results for AO have
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been established for both the unconstrained and constrained cases (Grippo and Sciandrone
(2000); Tseng (2001)). However, in our case the compatible sequence of apertures depends
on the choice of gantry speed. And because our aperture selection is done with a heuristic
procedure, performing Step 2 is not guaranteed to yield the optimal apertures for an (S,R)
combination. Therefore, we do not expect the AO to produce a globally optimal solution for
(VC).
Under this framework, the method can potentially inspect more (S,R) pairs since refining
the apertures will in general be faster than the initial aperture selection problem. However, no
guidance is available in the selection of new (S,R) points when the AO procedure terminates.
We augment the AO with a multi-start method that randomly generates initial S and R
values in the feasible region, and runs the AO procedure repeatedly from each initial value
to search for the best solution.
3.6 Experiments
Our test dataset includes five clinical prostate cancer patients cases (the same five cases
used in Chapter II), gathered from University of California at San Diego (UCSD) Moores
Cancer Center. There is one target (prostate) with a prescription dose of 79.2 Gy over
44 fractions, and three critical structures (bladder, rectum, femoral heads) besides normal
tissue. The dose volume histogram (DVH) criteria for evaluating the treatment plans are
summarized in Table 3.1. The patient volume is divided into a grid of voxels of size 4×4×2.5
mm3. This entire grid is used in the final dose calculation to evaluate the delivered dose under
a given treatment plan. However, in the optimization problem we consider a downsampled
grid, in which we keep one in every 8 voxels in the critical organs and one in every 64 voxels
in the normal tissue. For each patient the treatment includes one arc with 177 total control
points, and the treatment beam is discretized into 1×1 cm2 beamlets. The resulting problem
dimensions for all 5 patients are presented in Table 3.2. We use a set of machine parameters
(shown in Table 3.3) that resembles that of a Varian treatment machine.
72













Table 3.1: Clinical criteria for the prostate cancer cases.
Case voxels beamlets nonzero Dbmnj distance between control points (
◦)
δ3, . . . , δ176 δ2, δ177 δ1



































Table 3.2: Problem dimensions of the downsampled cases.
Our objective F is a smooth piece-wise quadratic function, which penalizes both over-
and under-dosing of each individual voxel in the target, and only overdosing of voxels in
the other structures. To facilitate comparison with the full VMAT plans, we use the same
weighting factors for different structures as those in Chapter II, and for the same of making
a comparison, the resulting treatment plans are scaled so that the dose distribution achieves
95% target coverage. Our algorithm is implemented in C++, with all convex optimization
problems solved using CPLEX 12.5. The evaluation of delivered dose and objective function
in the aperture selection procedure is implemented with the Parallel Programming and Com-
puting Platform (CUDA) to take advantage of the parallel computing power of the Graphics
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Processing Unit (GPU).
Dose rate gantry speed physical leaf speed distance from source
(MU/sec) (deg/sec) (cm/sec) (cm) (cm)
RL RU SL SU v SAD SCD
0 10 0.83 6.0 2.25 100 53.9
Table 3.3: Machine parameters used in VMATC experiments.
3.6.1 Exact vs direct search methods for refining apertures
In Section 3.4 we proposed two different methods for fine-tuning the leaf positions given
a complete plan with K control points. The exact method requires us to solve a number of
optimization problems and potentially requires much longer solution time compared to the
direct search method, however it guarantees the optimal leaf setting in each optimization
problem, whereas the direct search method is fast but only explores a finite number of
options. First we explore the tradeoff between solution time and quality by employing the
exact method in refining the set of selected apertures.
Expecting a long runtime for the exact method, we chose Case 2, the smallest case of the
five in the number of beamlets per beam, as the sample case for our experiment here. The
size of the problem is further reduced by using K = 34 total control points, each 10◦ apart.
We set S = SU so that the range of feasible leaf positions in each optimization problem is
the smallest, and chose R = 7.34 MU/sec randomly from the feasible range. Both methods
are tested under the same setting. We compare the objective function value in different
iterations (where one iteration determines the leaf setting in one row and one control point
at a time). Figure 3.3 shows the progression of the objective function vs iteration number
for the two methods.
The exact method outperforms the direct search method in each iteration in reducing the
objective function value. We stop this test when the apertures at every control point have


























Figure 3.3: Objective function value in exact and direct search methods for refining apertures
method is 1.8% better than that obtained by the direct search method. However, solving
the optimization problems for all refinement iterations only took 1.9 seconds for the direct
search method, whereas the exact method took 30,111.4 seconds (more than 8.3 hours). The
significant reduction in solution time clearly outweighs the slight loss of plan quality in using
the direct search method, which will become more pronounced if we apply these methods
to a case with a larger input dataset. Moreover, if we repeat the refinement procedure with
the direct search method for more iterations, the objective quickly reduces to below the
value obtained in the exact method. This comparison is shown in Figure 3.4. The direct
search method took a total of 21.1 seconds to converge, at which point no more than 0.1%
of objective improvements can be made after refining all leaf pairs at all control points. For
these reasons we will focus exclusively on the direct search method in the aperture selection
in the experiments below.
3.6.2 Overall strategy under frameworks A and B
For the remainder of this section we focus our attention on designing a treatment plan
within 30 minutes, a reasonable estimate of the maximum time available for treatment
planning in clinics. Within frameworks A and B, our strategy depends on how fast we can



























Figure 3.4: Objective function value in exact and direct search methods for refining apertures,
with the direct search method run until convergence
enough to allow the Nelder-Mead algorithm to converge quickly, we can pursue a multi-
start approach and explore different areas in the feasible region. However, if the aperture
selection time is long, we need to then look for a suitable starting simplex for the Nelder-
Mead algorithm that in general provides good solutions. On the other hand, in framework
B, the alternating optimization procedure is always embedded in a multi-start approach,
where whenever the AO converges, another (S,R) pair will be chosen randomly to initialize
the AO procedure again, until the time limit is reached.
Table 3.4 summarizes the average runtime of the aperture selection described in Section
3.4, calculated from 30 independent runs each associated with a random (S,R) pair. Note
that in framework B, from every starting (S,R) pair the AO procedure consists of performing
the aperture selection as well as (S,R) optimization potentially multiple times, the average
runtime may take longer than these reported values. We set the termination criteria so that
if no more than 0.1% improvement in the objective function can be made by repeating Step
3(b) in the algorithm, we terminate the search. The resulting runtimes range from just over
2 minutes to more than 6 minutes, which will only allow a few to a maximum of just over a
dozen (S,R) pairs to be explored in either frameworks.
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Case 1 2 3 4 5
Average runtime (s) 252.6 136.5 379.5 260.8 381.8
Table 3.4: Average runtime of the aperture selection problem from 30 random (S,R) pairs
3.6.2.1 Starting (S,R) point under Framework A
Given the observation above, the Nelder-Mead algorithm in framework A is not likely to
start and converge multiple times within the time limit, and therefore we need to look for
one particular simplex in the feasible region that in general leads to good solutions. The
number of vertices used to construct the simplex in the Nelder-Mead algorithm here equals
three, resulting in a triangle.
Again, without any information about the shape of function H̃(S,R), no theoretical
results exist to guide the choice. Therefore we need to test different configurations for the
triangle in terms of size and the area they cover. We terminate the Nelder-Mead algorithm
if the maximum difference in the objective values from all vertices is less than 0.1%. Figure
3.5 (a) shows the initial 15 triangles used in our tests. We take two large, four medium
and nine small triangles and spread them out to cover the entire feasible region. After the
Nelder-Mead algorithm reaches 30 minutes or terminates early (which in our case does not
happen in any test) from each starting triangle for each case, we put all final solutions in
a pool and plot the best 80%. From Figure 3.5 (b) we can see that these solutions are all
concentrated on the lower right half of the feasible region, which is reasonable since neither
low dose rate combined with high gantry speed, or high dose rate combined with low gantry
speed are likely to generate good quality plans. We fit these solutions to a line, and expand
the line in both directions to encompass the set of solutions. From this region we then
randomly generate five additional triangles. We repeat the generation process to find a set
of triangles that together cover most of this region, the results are shown in Figure 3.6, and
these triangles are tested in the Nelder-Mead algorithm.
At the end of the tests we compare the 20 solutions, started with the original 15 and the
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additional 5 triangles, for every individual case in terms of objective, treatment time and
total MU values in Figure 3.7, where all values are scaled to the average of the 20 solutions.
If we require that the objective function value as well as the treatment time be lower than
the average for all cases, only the medium triangle on the right bottom corner in Figure 3.5
(a), and the red triangle in Figure 3.6 can meet the requirement. Both are able to keep the
total MU under 105% of the average for all cases. In the subsequent tests, we use the latter
triangle for its ability to provide better objective function values in comparison.






































Figure 3.5: (a): 15 initial triangles tested in the Nelder-Mead algorithm; (b): (S,R) pairs
(stars) corresponding to the best 80% solutions


















Figure 3.6: 5 additional triangles tested in the Nelder-Mead algorithm
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Figure 3.7: Objective, treatment time and total MU comparison for all 20 triangles tested
in the Nelder-Mead algorithm. 1 — 9: small; 10 — 13: medium; 14 — 15: large; 16 — 20:
additional five triangles
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3.6.2.2 Performance under framework B
Next we compare the performance of framework B and framework A. In implementing
framework B, we terminate the the alternating optimization when no more than 0.1% im-
provement can be made in the optimization of (S,R). Once the AO stops, another initial
(S,R) pair is chosen to start the optimization again, until the time limit is reached.
We ran framework B independently for ten different times, each time randomly and
uniformly choosing an initial (S,R) pair. We keep the best solution encountered in each run
for all cases, and again plot the (S,R) pairs corresponding to the 80% of the best solutions
on the feasible region. We can see in Figure 3.8 that the solutions again in general lie within
a band close to the bottom right corner.
Based on this information, we adjust the way that the initial (S,R) pairs are sampled: we
first fit a line to these solutions, and uniformly generate a point along the line. Then the point
is moved perpendicularly to the line according to a normal distribution with mean 0 and
variance σ2, where σ2 is set to be equal to the variance of the distance from the set of points to
the fitted line. The (S,R) pairs generated this way stay close to the band of good solutions,
and still have a chance of exploring different areas in the feasible region. We ran framework
B again 10 times under this setting, and record the range of resulting objective, treatment
time and total MU values corresponding to these plans. Figure 3.9 shows these quantities
for all five patient cases, normalized to the solutions from framework A. Even though the
objective values under Framework B are better for case 5, for all other cases framework A
clearly outperforms framework B. Framework A also achieves good performance in terms of
treatment time and total MU values. Therefore we choose framework A over B in all the
remaining experiments below.
3.6.3 Comparison with VMAT plans
Finally, we compare the VMATC plans obtained from framework A to VMAT treatments,
for which we already have a method of optimizing the treatment plans (described in Chapter
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Figure 3.8: (S,R) pairs (star) corresponding to the best 80% solutions from 10 initial runs
under Framework B
II). In Table 3.5 we summarize the statistics of the VMATC plans versus those of the
corresponding VMAT plans. Out of the five test cases, VMATC actually outperforms the
full VMAT plans for 4 cases in terms of objective value and for 2 cases in terms of treatment
time. Moreover, the dose distributions for the VMATC plans are able to satisfy the same
set of DVH criteria as the corresponding VMAT plans with no significant deterioration in
quality, as can be seen from Figure 3.11. The only compromise in VMATC treatments is
that the total MU is in general considerably higher under VMATC. Without the ability to
dynamically control the gantry speed during the treatment, VMATC cannot quickly open up
or close apertures, or selectively turn off the source during the treatment. Therefore it has to
use smaller apertures throughout the treatment to avoid giving large amounts of dose from
unfavorable angles. Figure 3.10 shows the average size of active apertures (i.e., those that
have positive fluence rates), calculated by adding up the area of each open leaf row, for the
corresponding VMAT and VMATC treatment plans. The apertures used in VMAT plans are
significantly larger than those in VMATC plans on average, ranging between 42% — 90%
larger for the five cases tested. Having to use small apertures makes VMATC less effective
in delivering the prescribed dose, and leads to higher total MU values in comparison.
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Case modality treatment time (s) total MU runtime (s) objective value
1 VMAT 149.3 611.5 78.8 22279
VMATC 107.4 751.6 1800 21166
2 VMAT 149.3 667.7 71.5 41763
VMATC 110.8 1017.8 1800 42589
3 VMAT 141.1 539.0 59.2 33865
VMATC 171.4 979.1 1800 30985
4 VMAT 142.6 557.6 54.2 54344
VMATC 171.4 979.1 1800 52451
5 VMAT 155.5 610.4 67.6 32819
VMATC 176.6 1008.8 1800 30693
Table 3.5: VMATC and full VMAT treatment plans for cases 1-5
3.7 Conclusions
We developed two solution frameworks for the optimization problem for VMATC treat-
ments. We considered the optimization of the constant gantry speed and dose rate as well as
the apertures. We recommend the configuration under framework A that consistently pro-
vides high quality solution in terms of objective function value, total MU and total treatment
time. A comparison with VMAT on actual patient cases shows that VMATC is capable of
producing very high quality plans. However, the lack of the ability to dynamically change
the dose rate and gantry speed typically leads to higher total MU values for the VMATC
plans, and the treatment planning time is much longer compared to VMAT, for which the
optimization usually only takes around 1 minute to complete. Moreover, one set of opti-
mization parameters may not be suitable for multiple cancer sites and prescription doses,
and we may need to “retune” the implementation in these cases.
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Figure 3.9: Objective, treatment time and total MU of 10 plans under framework B (star)














































































































































































Many aspects of Intensity Modulated Radiation Therapy (IMRT) treatments are subject
to uncertainty, of which the most common is the uncertainty in the positions of the tumor
and its surrounding organs with respect to the treatment beams. The treatment is subject
to (i). uncertainties caused by the day-to-day variations in and after the setup process and
changes in the patient’s anatomy; and (ii). uncertainties during the treatment, caused by the
shifts in structures due to motions such as breathing and filling up of internal organs (see,
e.g., Langen and Jones (2001), Van Herk et al. (2004)). The former is usually referred to
as inter-fraction uncertainty, and the latter – intra-fraction uncertainty. These uncertainties
can lead to deviations of delivered dose from dose designed in the treatment planning process,
and compromise the quality of the actual treatment.
The conventional approach to accounting for uncertainties is to first define the Clinical
Target Volume (CTV), which includes the tumor and its immediately surrounding tissues
that likely contains cancerous cells, then add an internal margin to account for intra-fraction
motion which leads to the Internal Target Volume (ITV), and finally add a margin around the
ITV to produce the Planning Target Volume (PTV). The PTV is then used as the target in
the treatment planning process. The margin is intended to account for both inter- and intra-
fraction motions, and its size is determined based on statistics of the patient population (van
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Herk et al. (2000); Van Herk et al. (2004)). However, the use of margin might not adequately
model the dose delivered to different structures under uncertainty for several reasons: First.
shifts in the patient and/or organ position do not usually result in the same rigid shifts in
the dose distribution. In fact motions may heavily distort the dose distribution and lead to
under-dosing of the targets and/or over-dosing of the healthy structures; secondly, the use of
a uniform margin may not be appropriate, particularly when the target is closely surrounded
by critical structures. Overlap of the margin and other structures will likely cause the normal
structures to be over-dosed in delivering the treatment. Moreover, the margin-based model
uses only the aggregate dose of the entire treatment and disregards the per fraction dose,
which is important for certain targets and critical structures. As a result the delivered dose
in certain fractions may differ from the prescribed dose even when the aggregate planned
dose is adequate.
Many researchers have therefore explored various alternative approaches. In the field
of robust optimization, Chu et al. (2005) approximated the dose delivered to every voxel
as normally distributed assuming Central Limit Theorem (CLT), and calculated its mean
and variance using 7 pre-calculated scenarios and their probabilities. The authors then
proposed a robust LP with constraints on the probability of over- or under-dosing every voxel,
and solved the problem by transforming it first to a Second Order Cone Program (SOCP).
Similarly, Olafsson and Wright (2006) assumed normal cumulative dose and calculated its
mean and variance from 5 scenarios. An optimization problem was then formulated as an LP
with bounds on the delivered dose, and solved through an SOCP reformulation. However,
imposing the constraint that the probability of every single voxel meeting certain criteria
does not guarantee the collection of voxels will all meet those criteria, especially when the
number of voxels is very large. In a study to investigate the benefits of robust optimization
for intra-fraction breathing motion, Chan et al. (2006) and Bortfeld et al. (2008) associated
breathing phases with probability density function (pdf) and bounds on the pdf to model
uncertainty in motion patterns. The optimization of beam weight profile was done by solving
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an LP that took into account the uncertainty set. Relying on CLT, Sobotta et al. (2010)
assumed that the tail of the dose distribution under uncertainty resembled the tail of a
Gaussian distribution, and thus the mean, variance and the probability of the dose lying
in certain intervals of interest can be calculated. The authors suggested an optimization
problem that maximized the probability of finding the penalty function within the interval,
while imposing constraints on violation of that interval. Finally, Fredriksson et al. (2011)
applied min-max optimization and minimized the worst case penalty function in a number
of scenarios. However, the fact that the treatment is usually delivered over many fractions
means that the realized cumulative dose is generally far different from the dose in any of the
extreme cases, and the worst case optimization is too pessimistic.
Stochastic programming is also a method of choice when protection is sought against
uncertainty. Löf et al. (1999) solved a model that maximizes the expected value of a func-
tion of the probability of tumor control and normal tissue damage. However the authors
had to resort to Monte Carlo simulation methods for approximating the objective function
when the number of fractions N is above 5 because of computational difficulties. Li and
Xing (2000) modeled the expected dose to a voxel as the sum of the dose to a different
position, weighted by the probability of the voxel occupying that position, and penalized
the difference between the prescribed and expected dose for every voxel. The experiments
showed that the model achieved improved sparing of critical structures and similar target
coverage. Unkelbach and Oelfke (2005) employed a similar dose calculation method, but
incorporated the variance of dose in target voxels as part of the penalty function to ensure
homogeneous target dose. Baum et al. (2006) used coverage probability to represent the
probability of a point in space being covered by a certain organ under uncertainty, and the
objective function consisted of the sum of target and critical organ penalties weighted by
their respective coverage probability. These studies all relied on one assumption that may
not be appropriate in real-world situations: the dose distribution in space is assumed to
be constant regardless of motion and error. In reality any motion will inevitably change
87
the dose distribution, sometimes substantially. McShan et al. (2006) proposed a technique
called Multiple Instance Geometry Approximation (MIGA), which calculated the dose dis-
tribution for a number of scenarios, and the treatment plan optimization is performed using
the expected dose calculated from these scenarios. However, one potential issue with this
approach is that the number of scenarios used (seven) may not be large enough to capture
the distribution of uncertainty, or computational difficulties may become apparent. In a
tumor-tracking based approach, Nohadani et al. (2010) took advantage of the 4-D CT data
and separated the patient’s breathing motion into 6 phases, and proposed a model that op-
timized the intensity-phase combination and minimized the expected penalty. Finally, Men
et al. (2011) proposed an optimization problem that included expected penalties for both
the per-fraction dose and the cumulative dose. Assuming CLT, the expected penalty for the
cumulative dose was replaced by the penalty of the expected dose, and the per-fraction dose
was approximated by a large number of scenarios.
Many of the above-mentioned approaches relied on CLT, which was reasonable when
the number of fractions in the treatment was large. However, for treatments with only a
small number of fractions (a good example is Stereotactic Body Radiation Therapy (SBRT),
which involves treatments up to only 5 fractions), this assumption may not be appropriate
anymore. This also apples to the re-optimization of the treatment plans, where only the
remaining fractions in the treatment are considered.
Technological advances have made it possible to monitor the patient’s anatomy change,
fraction-to-fraction setup variations, as well as to reconstruct the actual dose distribution
using daily images of the patient (Mohan et al. (2005); Langen et al. (2005); Oldham et al.
(2005); Yang et al. (2007)). To exploit the additional information provided by these tech-
nologies, many techniques, which we all refer to as Adaptive Radiation Therapy (ART),
have been developed. Ferris and Voelker (2004) proposed a DP framework for determining
the optimal dose in each fraction of the treatment under random errors. The authors pro-
posed a neuro-dynamic programming (NDP) based heuristic that, at every stage, minimized
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the expected approximate terminal penalty assuming the same policy is applied henceforth.
The optimization is done by way of simulation, where 5 different shifts were used to model
the random errors in any scenario. Deng and Ferris (2008) employed the same solution
technique, except that a neural network was used in approximating the terminal penalty.
However, the strategies used are chosen from a pool of pre-selected decisions, which may
not be the best achievable. de la Zerda et al. (2007) combined closed-loop control theory
with ART, and proposed two adaptive optimization methods that, based on the knowledge
of the deviation in delivered dose and the geometry change, tried to correct the deviation
in the immediate next fraction and the remaining fractions respectively. However, the opti-
mizations were done without considering any uncertainty factors, even though motion was
expected in the treatment. Saka et al. (2011) followed a similar approach and optimized
the constant plan for all remaining fractions after taking the delivered dose and observed
geometry change into account. However the optimization model did not include any pro-
tection against uncertainty in the dose to be delivered. Finally, Sir et al. (2012) employed
the MIGA (McShan et al. (2006)) approach in modeling inter-fraction uncertainties, and in-
tegrated stochastic programming with open-loop feedback control to optimize the constant
plan to the end of the treatment. The nature of the stochastic programming approach means
that a larger number of fractions inevitably translates to significantly larger problem size.
Also realistic model of uncertainty requires potentially many scenarios, which can easily lead
to intractable optimization problems.
The goal of this research is to build upon the previous work done by the fore-mentioned
researchers, and achieve four things that, to our knowledge, have not all been considered by
any single research simultaneously:
• Adequately model the patient’s inter-fraction motion uncertainties;
• Take both per-fraction and cumulative dose evaluation criteria into account in the
optimization model;
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• Solve the stochastic programming problem with high, verifiable quality for real-world
cases with long treatment courses;
• Extend the optimization approach to cover adaptive radiation therapy, where central
limit theorem may not be an appropriate assumption in modeling the total dose to be
delivered.
The remainder of this chapter is organized as follows: first we describe the general assump-
tions and the optimization model in Section 4.2. We explain in detail our proposed solution
approach, and extend the approach to ART problems in Sections 4.4 and 4.4.4. In Section
4.5 we compare our model with the model proposed in Men et al. (2011), which is simpler
to implement in practice, under different settings. Finally we present numerical experiments
with real-world patient cases and results in Section 4.6.
4.2 The adaptive IMRT optimization model
LetN denote the total number of fractions in the treatment, and n the number of fractions
already delivered. Let s be a random scenario, defined by a rigid shift of the patient along the
three axes, and let p(n) = (s1, . . . , sn) be a random path consisting of n consecutive random
scenarios s1, . . . , sn. Note that throughout this chapter we use boldface letters to represent
random parameters, and regular font for parameters that are deterministic. In addition, let
D(·) denote the dose deposition matrix. If the argument is a scenario, it corresponds to the
dose deposition matrix under that scenario. On the other hand, if the argument is a path,
D(·) then equals the sum of all the dose deposition matrices under the series of scenarios in
that path. Moreover, let z̄(n) denote the dose already delivered in the first n fractions, and let
z(N−n)(·) denote the dose that is yet to be delivered in the next N − n fractions. Moreover,
to distinguish between dose delivered in one and multiple fractions, let zk(·) denote the dose
to be delivered in fraction k, k = 1, . . . , N . Finally, let L and C be the sets of evaluation
criteria that apply to fractional and cumulative dose, respectively, and let G`(·), ` ∈ L and
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Gc(·), c ∈ C be the the (convex) penalty term that applies to fractional and cumulative dose,
respectively.
The problem for adaptive IMRT under uncertainty can then be formulated as:













· (z̄(n) + z(N−n)(x,p(N−n)))
)]
subject to:
zn+1(x, s) = D(s)>x (4.1)
z(N−n)(x,p(N−n)) = D(p(N−n))>x (4.2)
x ∈ X. (4.3)
Here X is a compact feasible region for variable x. We minimize the sum of two expected
penalty terms: one that applies to the dose to be delivered in the immediate next fraction,
and another that applies to the average dose in the entire treatment course. Note that
since s and p(N−n) are random quantities, the dose to be delivered, namely zn+1(x, s) and
z(N−n)(x,p(N−n)), are also random. In this formulation, if n = 0 and thus z̄(n) = 0, the entire
treatment is yet to be delivered. On the other hand if n > 0, this formulation becomes an
adaptive model that takes delivered dose z̄(n) into account and re-optimizes the treatment
plan for each fraction in the remainder of the treatment.
Note that functions G`(z




· (z̄(n) + z(N−n)(x,p(N−n)))
)
implicitly de-
pend on matrices D(s) and D(p(N−n)). Since it depends on the patient’s internal geometry,
the relationship between the patient setup scenario and the dose deposition matrices cannot
be easily characterized mathematically. Therefore instead of solving problem (P) directly,
we apply a technique known as the Sample Average Approximation (SAA) (King and Wets
(1991); Kleywegt et al. (2002); Verweij et al. (2003); Linderoth et al. (2006)). We first ran-
domly draw samples from the distribution of p to replace the random parameters in the
penalty function. The true objective function value is then approximated with the average
of these samples. By doing this we essentially transformed problem (P) into a deterministic
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problem, where the samples are known parameters:
















· (z̄(n) + z(N−n)(x, p(N−n)i ))
)]
subject to:
zn+1(x, si) = D(si)
>x, ∀i = 1, . . . ,m
z(N−n)(x, p
(N−n)




>x, ∀i = 1, . . . ,m
x ∈ X.
Here si is the first in the series of scenarios in p
(N−n)
i for all i.
Note that if the number of samples m = ∞, problem (SAA) will become equivalent to
problem (P). However, in reality it is not possible to take an infinite number of samples,
and we must decide on the value of m before problem (SAA) can be formulated or solved.
Therefore we need to ensure that m is large enough so that our approximation of (P) with
(SAA) is adequate, i.e., the resulting objective function gm is close enough to g
∗.
4.3 Setting m a-priori
One possible option for selecting m is to choose a sufficiently large value a-priori, so
that the resulting objective function value at the optimal solution in the (SAA) has a high
probability of being a nearly-optimal solution to (P).












· (z̄(n) + z(N−n)(x,p(N−n)))
)]
is finite for all x ∈ X, Ruszczyński and Shapiro (2003) derived the number of samples m
needed for the solution to (SAA) to be have a high probability of being a nearly-solution to
(P). Let Ŝδm and S
ε represent the set of approximate solutions to (SAA) and (P) respectively,
defined by:















· (z̄(n) + z(N−n)(x, p(N−n)i ))
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≤ gm + δ},
and











· (z̄(n) + z(N−n)(x,p(N−n)))
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≤ g∗ + ε}.












where D := supx,y∈X ‖x− y‖ is the diameter of the feasible region X, η is the dimensionality
of the feasible region, and L is the Lipschitz constant of the penalty function, defined such
that:
|g(x)− g(y)| ≤ L‖x− y‖




























· (z̄(n) + z(N−n)(x,p(N−n)))
)]
.
To estimate m with (4.4), we need to know the values of L and σ2max. The main difficulty
in finding these values is that the distribution of the patient’s position does not directly
translate to the distribution of the delivered dose. Because the calculation of the dose
deposition matrix involves applying a model of the physical interaction of the radiation
particle with the patient’s body, it cannot be effectively accounted for in calculating σ2max.
Moreover, as the authors mentioned in Ruszczyński and Shapiro (2003), the bound resulting
from (4.4) is typically too conservative to be used practically.
For these reasons, rather than searching for valuem a-priori, we use an alternative method
that sets m dynamically.
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4.4 Monte-Carlo bounding techniques
Before discussing how we can choose the value of m in problem (SAA), we need to
examine in detail how we can find the range in which the optimal objective value of (P)
resides. This is done by finding both an upper and lower bound for g∗. We first state the
analysis for a general problem:
(SP) h∗ = min
y∈Y
E[f(y, ξ)], with y∗ = arg min
y∈Y
E[f(y, ξ)],
where y is the vector of decision variables and Y is a compact feasible region. It is reasonable
to assume that E[f(y, ξ)] <∞ for every y ∈ Y , or we can shrink the region Y to only include
points that satisfy this requirement. Moreover, ξ is the vector of random parameters, and
assume that f(y, ξ) is a convex function for any given ξ.
Assuming that function E[f(y, ξ)] is too complex or large to be computed or optimized
directly, we take advantage of the SAA approach. Taking m i.i.d. samples ξi from the
distribution of ξ, we construct the following approximating problem:













The Monte-Carlo bounding method focuses on verifying the quality of the solution to (SP)m
by establishing a confidence interval on h∗.
4.4.1 Lower bound













Here we paraphrase the proof as follows: first note that
h∗ = min
y∈Y

















i), it immediately follows that for every

































1, . . . , ξm), ξi
)]
= E[hm].
This leads to the lower bound on h∗.
For the same reasons that we cannot solve problem (SP), in practice the value E(hm) is







Here we solve a total of M (SPm) problems, each of which is formulated with independent
sample groups ξi1, ξi2, . . . , ξiM , i = 1, . . . ,m, and him is the optimal objective function value
of the i-th such problem, obtained at yim. Then the average of these objective values can be
used as an estimator of the lower bound E[hm].
4.4.2 Upper bound
Because y∗ is the optimal solution to problem (SP), we can readily see that:
E[f(ŷ, ξ)] ≥ E[f(y∗, ξ)] = h∗ for any ŷ ∈ Y.
Therefore we can find an upper bound on h∗ by finding E[f(ŷ, ξ)] for some ŷ. Of course we
want the resulting upper bound E[f(ŷ, ξ)] to be as close to g∗ as possible. This is done by
selecting ŷ from the set of points that are already promising in coming close to y∗. Recall
that the lower bound on h∗ is found by solving M SAA problems. The solutions yim are our
best attempt at finding the approximate optimal solution to problem (SP), and we use these
solutions here to calculate the upper bound on h∗.
Again, in practice the expected value E[f(ŷ, ξ)] can be estimated by taking a large
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number of samples, and using the sample mean estimator:





where K is a large number.
4.4.3 Calculating the confidence intervals
In the above analysis, both the upper and lower bounds are calculated using samples.
This can help us find a confidence interval on the value h∗. As long as we use sufficiently
large number of samples M and K, it is appropriate to assume that Central Limit Theorem
applies. We have:
√
M(L(M)− E[hm]) ∼ N(0, σ2m), and
√
K (U(K)− E[f(ŷ, ξ)]) ∼ N(0, σ̄2(ŷ))
where σ2m = var(hm), and σ
2(ŷ) = var (f(ŷ, ξ)). These variance values can be approximated
by the sample variances:











Now let α be the confidence level we want to achieve, and let Tn be a random variable
that has a t-distribution with degree of freedom n− 1, and let tn−1,α satisfy:
P{Tn ≤ tn−1,α} = 1− α.










Assuming that the samples in estimating the upper and lower bounds are independent of
each other, we have:
P {L(M)− ε` ≤ E[hm] ≤ h∗ ≤ E[f(ŷ, ξ)] ≤ U(K) + εu}
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= 1− P {L(M)− ε` ≥ E[hm], or E[f(ŷ, ξ)] ≥ U(K) + εu}
≥ 1− (P{L(M)− ε` ≥ E[hm]}+ P{E[f(ŷ, ξ)] ≥ U(K) + εu})






Therefore we can use
[L(M)− ε`, U(K) + εu] (4.5)
as the confidence interval for h∗ with confidence level α.
4.4.4 Applying the bounding technique to problem (P)
Now we can apply the Monte-Carlo bounding technique to problem (P), and use (SAA)















· (z̄(n) + z(N−n)(x, p(N−n)i ))
)
i = 1, . . . ,m.








We can see that the results in Section 4.4 can be applied directly here:
E[gm] ≤ g∗ ≤ E[G(x̂,p(N−n))], for any x̂ ∈ X. (4.6)
This gives rise to the following procedure for determining the sample size and solving
problem (P) with (SAA).
Dynamic sampling procedure
1. Determine initial sample size m, batch size M and sample size K. These can be picked
arbitrarily as the starting point. Set the confidence level α, and determine the stopping
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criteria for this procedure based on the relative size of the confidence interval.




2,j , . . . , p
(N−n)
m,j , j = 1, . . . ,M .
Formulate an (SAA) problem with every batch of sample paths, solve a total of M







G(x, p(N−n)i,j ) for j = 1, . . . ,M






G(x, p(N−n)i,j ) for j = 1, . . . ,M.
By averaging the resulting objective values from all of the (SAA) problems, obtain the







3. Obtain K independent samples p
(N−n)
1 , . . . , p
(N−n)
K , and calculate for all candidate so-








k ), ∀j = 1, . . . ,M.




Moreover, define the corresponding solution as:




























From (4.5) we know that the 1− α confidence interval on g∗ is:
[L(M)− ε`, U(K) + εu].
5. If the confidence interval obtained in Step 4 satisfies the stopping criteria, terminate;
otherwise increase M or m or K, and go to Step 2.
When the algorithm terminates, we can use the solution x̂ as the approximate solution
to problem (P). We show in Appendix C that when the numbers m, M, and K → ∞, gm
as well as both L(M), U(K) will converge to g∗. Therefore this procedure will eventually
converge for any confidence level α and any arbitrarily tight stopping criteria. Note that, as
we show in the numerical experiments below, the actual number of samples m, M and K do
not have to be very large in order for us to find a satisfactory solution.
4.5 Comparison with a model in the literature
Men et al. (2011) proposed a similar model in dealing with inter-fraction uncertainties
in the plan optimization for the entire treatment. When the number of fractions in the
treatment is large enough to justify the law of large numbers (LLN) assumption, the authors










































while imposing the same constraints (4.1) (4.2) and (4.3). The assumption behind the
approximation is the convergence of the average dose to the expected dose. In solving this



























i.e., the expected penalty associated with fractional dose is approximated with the average
of penalty in m′ scenarios, and the expected dose is approximated with the average dose of
m′ scenarios.
This model is promising and easy to use in that it only requires solving one single op-
timization problem, and the solution can be used as the treatment plan. However, it could
not provide a measure of the quality the approximating solution and objective compared to
the original problem. Moreover, the LLN assumption relies on a large number of fractions in
the path p, which means it might not work as well in designing adaptive treatments where
the path may only contain a few fractions. We want to compare our SAA framework with
approach (CH), and explore two things in particular:
1. is model (CH) good enough in approximating the true objective g∗ and obtaining a
good solution?
2. is the above still true for n > 0, i.e., in the re-optimization framework?























In other words, the objective in (CH) is an under-estimator of the true objective at any
solution. However, we are most interested in the quality of the objective at its optimal
solution x̄. We can evaluate it by performing the paired t-test. The paired t-test compares
the mean of two random variables, which in our case are functions G(x̂,p(N)) and G(x̄,p(N)).
Here x̂ is the terminal solution provided by the dynamic sampling procedure. The null










To carry out the test, first we draw a large number, e.g., K ′, of sample paths from the
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distribution of p(N), and calculate:
dk = G(x̂,p(N)k )− G(x̄,p
(N)





















Under the null hypothesis, T follows the t-distribution with degree of freedom K ′−1. Given
confidence level α, we can look up the t-distribution table and find the corresponding p-value
for T . If the p-value is higher than our confidence level α, we then accept the null hypothesis,
and say that the two solutions x̂ and x̄ produce the same objective function value; otherwise

































depends on the (LLN) assumption: the average of a large number N independent and
identically distributed (i.i.d.) random variables is close to the expected value. When the
number of fractions to be delivered becomes smaller, this assumption may not apply anymore.











































We test the performance of this model in solving the adaptive optimization problems,
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and compare its solutions to the (SAA) solutions in Section 4.6.3.
4.6 Experiments
We compare our algorithms on four prostate patient cases, exported from an imaging
and treatment planning system at Department of Radiation Oncology at the University of
Florida. All patients are treated with 9 equispaced 60Co beams at angles 0◦, 40◦, 80◦, 120◦,
160◦, 200◦, 240◦, 280◦ and 320◦ respectively. The size of the beam is 40×40 cm2, and the
beamlets are of size 1×1 cm2. In discretizing the patients’ geometry, we used a grid consisting
of voxels of size 4×4×4 mm3. In the optimization model we used a downsampled grid of size
8×8×8 mm3 in unspecified tissues. However, in evaluating the final dose we always use the
full resolution grid. All of our test cases have one target (prostate) with a prescription dose
of 73.8 Gy to be delivered over 41 daily fractions. The critical structures include rectum,
bladder and femoral heads in addition to normal tissue.
The patient setup location is assumed to be jointly normally distributed with mean of
0 and standard deviation of 3mm along each of the three axes (see Ekberg et al. (1998);
Tinger et al. (1998); Van Herk et al. (2004)). Assuming that large errors will be detected
and corrected prior to the treatment, we restrict the error along each axis to be within
±6mm. Note, however, that our model and solution procedure does not require the normal
distribution assumption, and they work in principle with any distribution appropriate in
modeling the specific motion type. For each case, we randomly sample 500 setup scenarios
by perturbing the patient’s position according to this distribution, and use this collection
of scenarios as an approximation of the continuous space of random setup locations. All of
the sample scenarios and paths used in the optimization problems are then drawn from this
pool of 500 samples. The sizes of relevant parameters are listed in Figure 4.1. The number
of non-zero elements in the dose deposition matrix is not a constant any more, as shifts in
the patient position relative to the beams will affect the number of voxels irradiated by the
same beamlet, and thus affecting the total number of non-zero entries in the dose deposition
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matrix.
Case # voxels (total / down-sampled) # beamlets # non-zero elements in D(s)
1 226,324 / 38,731 2,318 2,908,444 – 3,103,615
2 205,911 / 35,988 2,336 3,320,876 – 3,432,446
3 131,216 / 22,330 2,002 2,074,564 – 2,124,810
4 162,628 / 29,828 2,413 3,232,972 – 3,273,917
Table 4.1: Problem dimensions of our test cases.
The penalty function used in all of our experiments are one-sided quadratic functions
that are based on voxel dose, having the same structure as the ones used in Men et al.
















max{zj − Tt, 0}2 ∀t ∈ T ∪O, c ∈ C,
where T and O are the set of targets and critical structures, respectively, vt is the collection
of voxels in structure t, and Tt is the threshold value for the dose delivered to a voxel in
structure t. Moreover, w`t and w
c
t are the weights assigned to structure t in function G` and
Gc (` ∈ L, c ∈ C), respectively. Our experiments are performed on a Mac Pro with 2×2.8
GHz Quad-core Xeon CPUs and 14 GB of memory. All of the optimization problems are
solved with an in-house interior point method based solver (see Wright (1987); Aleman et al.
(2010) for a description of the interior-point method), implemented in Matlab version 7.14.
The DVH constraints and criteria for evaluating the treatment plans are established
based on RTOG protocols (Radiation Therapy Oncology Group (2004)). Those defined for
the critical structures are summarized in Table 4.2. In establishing the constraints for the
target, for the margin-based model we followed the traditional approach and required that
95% of the PTV voxels receive the prescription dose, ≥99% receive 93% of the prescription
dose, and ≤ 10% receive more than 110% of the prescription dose. For the stochastic model,
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since we removed the margin and only took the ITV into account, we want to cover the
entire ITV with prescription dose under all circumstances; in addition, we require that none
of the ITV voxels receive more than 110% of the prescription dose.
Structure Rectum Bladder Femoral heads
Threshold dose (Gy) 75 70 65 40 65 40 50 45 40
Upper limit on volume (%) 15 25 35 45 17 35 10 25 40
Table 4.2: DVH criteria for critical structures.
One of the major challenges in comparing different plan optimization models is that the
process of adjusting the parameters to meet the DVH constraints is highly subjective and
model dependent. The margin built around the ITV in the conventional models leads to
a larger target volume, and usually also introduces overlaps with the surrounding critical
structures. These differences in the structure sizes, combined with different dose constraints
for the target, necessitate tuning the parameters for individual models. This is done to best
meet the DVH requirements while taking into account the trade-off between structures and
clinical considerations.
After the tuning is done, the same models are applied to all patients to eliminate further
variations that may be introduced by additional tuning for individual patient cases. In order
to facilitate the comparison across different cases, the treatment plans obtained from the
margin-based model are scaled so that 95% of the total PTV volume receive the prescription
dose under the nominal scenario.
After the plans from the margin-based model and the stochastic model have been gener-
ated, we apply them to the same set of 5 simulated treatment paths, each consisting of 41
fractions. For the following comparisons, we only inspect the target dose distributions based
on ITV dose, as the ITV is the region we are interested in covering with prescription dose.
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4.6.1 Comparing the stochastic model with the conventional model
We use our first experiment to show how directly taking randomness into account affects
the treatment quality in a random setting. We first set n = 0 and z̄(n) = 0 and find an
approximate solution to problem (P) using the procedure described in Section 4.4.4. This is
equivalent to designing an initial plan at the beginning of the treatment, without performing
any adaptive re-planning. In Table 4.3 we summarize the sizes of different samples used in
the solution process, and the runtime for one (SAA) problem as well as the bound obtained
on the objective g∗ for both cases. For the same case, the runtime for the (SAA) problems
are not identical in different runs, however they are very similar to each other because of the
similar problem sizes, and therefore we report only one representative statistic. Observe that
the number of samples m that we need in the (SAA) problem is rather small, showing that
(SAA) is very efficient in approximating problem (P) and in finding high quality solutions.
However, doing this requires solving the (SAA) problem M times, which may lead to long
treatment planning time.
Case sample size m batch size M sample size K bound on g∗ (SAA) runtime
1 30 20 100 2.1% 235 s
2 30 25 100 0.9% 307 s
3 30 30 100 5.4% 181 s
4 30 25 100 5.5% 319 s
Table 4.3: Sample sizes and bounds in the initial (SAA) problem.
The solutions are then applied to the 5 sample treatments, and the resulting DVH is
compared with DVH obtained from applying the margin-based solutions. We combine the
DVH curves for each patient of 5 sample treatments, and the result is a “cloud” of curves,
presented in Figure 4.1 for our test cases.
It can be observed that the treatments benefit from taking advantage of the stochastic
model. The stochastic plans are in general providing similar or better target coverage without
introducing additional hotspots, and can reduce the dose delivered to especially the rectum
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and the bladder which in general receive high doses. Although the femoral heads and skin
receive higher doses at the very low dose ranges, these structures under the stochastic plans
can still easily meet the same set of criteria compared to the conventional plans.
































































































Figure 4.1: DVH clouds for the stochastic plans (solid) and the conventional plans (dashed)
for 5 sample treatments
Another criterion important to the clinicians is the probability of delivering the pre-
scribed dose to the ITV in each fraction. As mentioned before, ensuring the target receives
the prescription dose not only over the entire treatment, but also in each fraction is critical
in a successful treatment. For both the conventional plan and the stochastic plan, we use
100 randomly sampled scenarios to evaluate the probability of a particular fraction of tar-
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get voxels receiving the prescription dose. The results are shown in Figure 4.2. In general
the stochastic model is able to achieve higher target coverage compared to the conventional
model. For Case 3, more than 24% of the bladder and more than 16% of the rectum overlap
with the PTV. By ignoring the normal tissue in the overlapped regions, the conventional
model compromises the rectum and bladder to provide better target target coverage. How-
ever, if we adjust the stochastic model to put more emphasis on the per-fraction effects, even
for Case 3 a higher coverage probability can be achieved (Figure 4.3).

















































































































Figure 4.2: Probability of covering a % volume of the ITV in one fraction for conventional
vs. stochastic plans
4.6.2 Re-optimization and adaptive radiation therapy
Being able to collect and exploit additional information about the delivered dose provides
us the opportunity to explore the benefits of adaptive radiation therapy. Due to the ran-
domness in the treatments the delivered dose distribution may differ from the planned one,
and adaptive re-optimization makes it possible to react to and correct the deviations in the
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Figure 4.3: Coverage probability for conventional vs. adjusted stochastic plan, Case 3
delivered dose and achieve potential additional benefits compared to performing stochastic
optimization alone. As mentioned in Section 4.2, our dynamic sampling framework also
works for designing adaptive treatments when updated information about delivered dose
becomes available during the treatment course.
We next investigate the effects of applying re-optimization during the simulated treat-
ment. Recall that if n > 0, which means n fractions have been carried out, solving model
(P) will be re-optimizing the treatment plan for the rest of the N − n fractions, taking into
account the delivered dose z̄(n). Here we assign to z̄(n) the dose delivered to the patient
in the first n fractions of the simulated treatments, and re-optimize the plan given this in-
formation. We then apply the updated treatment plan to the remaining fractions in the
treatments. The results are compared with the stochastic optimization plans on the same
simulated treatment courses.
In order to compare different re-optimization schedules we tested two schemes: one where
re-optimization is done once at the midpoint of the treatment, and another where we perform
weekly re-optimization for every treatment course. We will focus on for Case 1, for which the
trade-off between the target and the critical structures is more evident and the differences in
the results can be more readily seen. Table 4.4 shows the sample numbers m,M and K used
and the associated bounds in these experiments. It is interesting to notice that the runtime
depends heavily on the number of samples m but not much on the number of fractions left
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in the treatment course.
Scheme fraction sample path m M K bound on g∗ (SAA) runtime (s)
Reopt once 20 1 30 20 100 2.4% 297
2 25 25 2.1% 240
3 30 20 2.0% 293
4 30 20 1.8% 290
5 30 25 2.4% 280
Reopt weekly 7 1 30 25 100 5.1% 272
2 25 20 5.2% 229
3 25 20 3.8%
4 25 20 5.0%
5 25 25 5.3%
14 1 30 25 100 5.3% 274
2 25 20 4.5% 226
3 25 20 4.7%
4 25 20 5.8%
5 25 25 4.6%
21 1 30 25 100 4.2% 278
2 25 20 1.8% 229
3 25 20 2.5%
4 25 20 5.9%
5 25 25 4.8%
28 1 30 25 100 2.1% 320
2 25 20 3.0% 261
3 25 20 1.9%
4 25 20 1.1%
5 25 25 4.9%
35 1 30 25 100 1.1% 380
2 25 20 1.2% 274
3 25 20 1.3%
4 25 20 0.9%
5 25 25 1.9%
Table 4.4: Sample sizes and bounds on the objective function in the adaptive reoptimization
problems for Case 1.
Figure 4.4 shows the DVH cloud for both cases. Notice that the rectum and the bladder
both receive higher dose under the adaptive optimization schemes. However, from Figure 4.5
we can clearly see that the later the reoptimization takes place, the more the target coverage
probability for the reoptimized plans improves. Because the per-fraction and cumulative dose
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criteria are conflicting, this results in more dose being delivered to the critical structures close
to the ITV.
We offer a qualitative explanation of why performing reoptimization gives more dose to
the target region. Recall that the objective function in the adaptive optimization model















· (z̄(n) + z(N−n)(x, p(N−n)i ))
)]
.
For the cumulative term, the intensity vector x only affects future fractions n + 1 to N .
Therefore as more fractions are delivered, increasing x has less effect on the cumulative
dose and thus on the penalty term associated with it. This can be verified by examining
the (SAA) solutions for reoptimization at fractions 8, 15, 22, 29 and 36, respectively, in
one sample treatment for Case 1. For each adaptive optimization problem, we increase the
optimal intensity by 10% and calculate the average increase in the cumulative dose for each
structure over m different samples. The results in Table 4.5 confirm that x has much smaller
effect on the cumulative dose as n grows. On the other hand, x affects the per-fraction
penalty term the same way regardless of n, as the penalty depends on dose in fraction n+ 1
only. As a result, re-optimization towards the end of the treatment course will increase the
dose in the target region and thus the dose to the surrounding structures.
Fraction Increase in cumulative dose (%)
number normal tissue femoral heads rectum bladder ITV
8 8.3 8.3 8.3 8.2 8.3
15 6.6 6.6 6.6 6.7 6.6
22 4.8 4.8 5.0 4.9 4.9
29 3.1 3.0 3.3 3.5 3.2
36 1.4 1.3 1.6 1.6 1.5
Table 4.5: Effect on cumulative dose of increasing the intensity by 10% at different stages of
the treatment course.
It can be concluded that under the current framework, adaptive optimization puts more
110
emphasis on target coverage than critical structure sparing, especially when the number of
remaining fractions is small. This is an important factor to consider when applying adaptive
optimization with this model.
4.6.3 Comparison with model (CH)
In this section, we compare our model with the one proposed in (Men et al. (2011)). As
discussed in Section 4.5, model (CH) is easier to implement, and does not require solving
multiple optimization problems. However, it does not provide any measure of the solution
quality. On the same set of cases, we compare the solution quality of the plans obtained
from our model and model (CH).
4.6.3.1 Initial optimization problem
We follow the authors’ method in implementing model (CH), and use m′ = 100 samples
in estimating the expected penalty and the expected dose in model (CH), and apply the same
set of parameters in defining the penalty terms. Table 4.6 includes results of the objective
value comparison for our solution and the solution from (CH) for the initial optimization
problem. For all cases except Case 3, the p-values are much smaller than the critical value
0.05, and it is statistically significant enough to show that the true objective value at x̂ is
lower than that at x̄. For Case 3, the p-value is also very close to 0.05. However, the difference
in objective values are only around a few percent, which can be expected as (CH) is designed
to be a good approximation to (P) when N is large. The solution time for model (CH) is
much shorter compared to (SAA). In Figures 4.6 and 4.7 we compare the simulated dose and
coverage probability to our plans. While the cumulative dose to the critical structures, most
notably rectum and bladder, is higher for all cases under model (CH), the target coverage
probabilities are in general better for the corresponding solutions.
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Case estimated obj. U(K) p-value 95% c.i. for G(x̂,p(N))− G(x̄,p(N)) (CH) runtime
1 3709.1 0.003 [-114.2, -24.1] 48
2 3132.6 0.094 [-189.0, 15.2] 48
3 4663.3 <0.1% [-277.9, -107.0] 29
4 3596.1 <0.1% [-210.0, -82.7] 45
Table 4.6: Comparison of (SAA) solution x̂ with solution from model (CH) for the initial
stochastic optimization problem
4.6.3.2 Adaptive optimization problems
Finally, we perform the same tests to compare the expected objective function values for
the adaptive optimization problems. In order to fairly compare the outcomes from different
optimization models, the input dose used in the respective problem, in other words, z̄(n),
must be consistent. We therefore apply the initial and adaptive solutions from our model
until the fraction the comparison takes place. Then model (CH) is solved and its solutions
compared to our model. The results in Tables 4.7 and 4.8 show that for all but a few cases,
our solutions are similar to or better than the solutions from model (CH). It is interesting to
see that model (CH) performed very well in all cases, using much shorter optimization time
than (SAA).
Fraction sample estimated objective U(K) p-value 95% c.i (CH) runtime (s)
20 1 3613.0 0.013 [-69.9, -8.3] 62
2 3788.1 0.001 [26.0, 98.7] 58
3 3811.8 0.008 [23.6, 151.7] 58
4 3662.0 <0.1% [-97.3, -39.1] 54
5 3809.0 <0.1% [59.8, 103.1] 60
Table 4.7: Comparison of (SAA) solutions with those from model (CH) for reoptimization
problems under one-time reoptimization for Case 1
Intuitively, the LLN assumption that the average of i.i.d. random samples equals the
expected value becomes less accurate the fewer the number of samples. However, we do not
observe any deterioration in solution quality in the adaptive solutions from applying model
(CH). This is because as n increases, a larger portion of the overall dose is delivered. Even
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Fraction sample estimated objective U(K) p-value 95% c.i (CH) runtime (s)
8 1 3760.1 0.063 [-25.5, 0.70] 46
2 3661.1 <0.1% [-119.8, -87.0] 52
3 3705.1 <0.1% [-99.9, -75.4] 49
4 3785.9 <0.1% [-110.4, -101.9] 49
5 3798.1 0.98 [-85.1, 87.7] 48
15 1 3741.8 0.018 [-29.8, -2.9] 49
2 3735.9 <0.1% [-85.0, -27.7] 54
3 3691.7 <0.1% [-88.3, -62.6] 51
4 3708.1 <0.1% [-86.1, -54.7] 50
5 3805.1 0.22 [-101.1, 23.9 ] 53
22 1 3782.0 0.25 [-37.5, 9.9] 52
2 3703.1 0.001 [-80.1, -23.3] 62
3 3697.8 <0.1% [-111.2, -42.3] 63
4 3817.7 0.001 [-83.2, -21.1] 54
5 3782.5 0.86 [-42.1, 50.0] 57
29 1 3786.7 0.57 [-70.2, 38.7] 67
2 3716.3 <0.1% [-82.3, -27.0] 49
3 3757.6 0.612 [-18.1, 30.6] 61
4 3825.9 0.08 [-65.0, 3.9] 70
5 3754.2 0.468 [-53.2, 24.6] 65
36 1 3763.0 0.17 [-83.6, 14.7] 111
2 3736.4 0.547 [-66.2, 35.3] 125
3 3688.9 <0.1% [-164.7, -73.7] 108
4 3731.5 0.44 [-65.8, 28.9] 96
5 3842.3 <0.1% [91.4, 134.7] 109
Table 4.8: Comparison of (SAA) solutions with those from model (CH) for weekly reopti-
mization problems for Case 1
though the difference between the actual and expected dose over the remaining fractions
becomes bigger, this difference is “diluted” by the delivered dose. We test this empirically
with one sample path: at fractions 8, 15, 22, 29 and 36 respectively, calculate the expected
dose over the remaining N −n fractions based on the optimal solution obtained from model
(CH). Then we randomly sample 10 paths of N − n fractions, and calculate the actual
dose over each path with the same solution from (CH). The absolute difference between
the expected and actual doses for each path is calculated, and averaged over the 10 paths.
Table 4.9 lists the relative difference for all five structures. The relative difference increases
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with n for all structures, indicating that the LLN assumption is less and less applicable
when n grows. However, comparing the expected and actual cumulative dose over the entire
treatment in Table 4.10 reveals that the impact on the overall dose becomes much smaller.
Fraction Difference in expected and actual dose (%)
number n+ 1 normal tissue femoral heads rectum bladder ITV
8 0.05 0.7 1.2 1.9 0.04
15 0.07 1.0 1.2 1.7 0.04
22 0.05 1.3 1.1 2.6 0.07
29 0.11 2.3 1.6 2.8 0.09
36 0.09 3.6 1.5 2.7 0.1
Table 4.9: Relative difference between actual and expected dose over the undelivered frac-
tions at different stages of the treatment course
Fraction Difference in expected and actual dose (%)
number n+ 1 normal tissue femoral heads rectum bladder ITV
8 0.04 0.6 1.0 1.6 0.03
15 0.04 0.6 0.8 1.1 0.02
22 0.02 0.6 0.6 1.3 0.03
29 0.03 0.7 0.5 0.9 0.03
36 0.01 0.5 0.2 0.4 0.02
Table 4.10: Relative difference between actual and expected dose over the entire treatment
at different stages of the treatment course
Finally, we apply model (CH) in performing the adaptive optimization, and obtain the
DVH clouds for the overall dose in the sample treatments, as well as the target coverage
probabilities in Figures 4.8 and 4.9. Similar to the observation in the initial optimization,
model (CH) tends to emphasize the per-fraction target coverage, and results in more dose
to the critical organs in general.
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4.7 Conclusions
We investigated a stochastic programming based model that minimizes the expected
penalty based on both the per-fraction and cumulative doses. By solving a sample average
approximation model we can greatly reduce the complexity required in solving the proposed
model. Also, a statistical bound on the true objective function can be established by applying
the dynamic sampling procedure. Experiments with real patient data show that our approach
achieves improvements over the conventional, margin-based model in target coverage as
well as overall dose distribution. Our model can easily be extended to adaptive treatment
planning. However, in the adaptive optimization problems the solution lays more stress on
the target coverage and therefore results in higher dose to the surrounding structures. This
effect can be undesirable and needs to be factored in when using this model. Moreover, our
model requires solving multiple optimization problems, which is time consuming without
using any parallel computation. A comparable but simpler model proposed in the literature
is shown to provide moderately deteriorated but still satisfactory results.
115














































Figure 4.4: DVH clouds for the initial stochastic plans (solid) and adaptive plans (dashed)
for Case 1 in five sample treatments. Left: reoptimizing once, right: weekly reoptimization








































































































































Figure 4.5: Coverage probability for initial stochastic and adaptive plans for Cases 1. (a):
reoptimizing once at fraction 20; (b-1) — (b-5): weekly reoptimization at fractions 8, 15, 22,
29, and 36, respectively
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Figure 4.6: DVH clouds for the stochastic plans (solid) and the plans from model (CH)
(dashed) without adaptive reoptimization for 5 sample treatments
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Figure 4.7: Probability of covering a certain volume of the ITV in one fraction for stochastic
plans vs. plans obtained by solving model (CH)














































Figure 4.8: DVH clouds for the adaptive (SAA) plans (solid) and the adaptive plans from
model (CH) (dashed) of 5 sample treatments for Case 1. Left: reoptimization once; right:
weekly reoptimization
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Figure 4.9: Probability of covering a certain volume of the ITV in one fraction for adaptive
stochastic plans vs. adaptive plans from model (CH) for Case 1. (a): reoptimizing once




Conclusions and Future Research
Radiation therapy is a complex yet exciting field that interacts with medicine, physics,
operations research as well as many other subjects. While it has been an active field for many
years, new treatment methods and technologies emerge, and bring with them problems that
require unconventional optimization models and algorithms. In particular, the treatment
plan optimization problem for VMAT is still a difficult one due to the large problem size and
the restrictions due to the continuous gantry movement. While most optimization methods
resort to heuristics, our research can serve as a step towards explicitly incorporating all
machine constraints, and eventually an exact solution algorithm for VMAT.
On the other hand, the tradeoff between the large capital expenditure required in updat-
ing to a dedicated VMAT system and the potential benefits is an important factor to consider
when clinics are transitioning to VMAT treatment systems. By developing a treatment plan-
ning method for VMATC, we offer an alternative treatment that can be implemented on the
existing IMRT systems, and provides similar plan quality to VMAT treatments.
Accounting for uncertain events that happen between and during radiation therapy treat-
ments is important to ensure the outcome of the actual treatment. Even though advances in
imaging and patient monitoring technologies have made it possible to detect small changes
in the patient setup process as well as their internal geometries, radiation therapy treatment
can still benefit from directly incorporating uncertainty in the optimization.
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Finally, many of the algorithms we developed for solving radiation therapy treatment
planning problems can be applied or modified to solve other problems that involve large-
scale, nonlinear optimization systems.
Despite our best effort, we can only address a limited number of issues in this thesis.
There are still many interesting problems to be studied.
5.1 VMAT treatment plan optimization problem
For the VMAT treatment plan optimization problem, the greedy nature of the algorithm
dictates that apertures added earlier in the column generation process may not be good
choices later. A possible improvement is to study how ineffective apertures, in addition to
those with zero intensities, can be detected during the solution process.
In theory, the optimal VMAT plans will always outperform VMATC plans due to the
additional degrees of freedom. However, compared to VMATC, many of the VMAT plans
actually performed worse in terms of objective value, as seen in Table 3.5. We can poten-
tially find better solutions by introducing a refinement step similar to that used in VMATC
optimization, which improves the aperture shapes and/or fluence rates during or after the
column generation process, although this means that the optimization procedure will re-
quire more time to complete. Moreover, using the VMATC solution as the starting point for
VMAT optimization can also be a promising direction to pursue.
Reducing the treatment time and total MU values are not considered explicitly in the
column generation procedure. However, these are important factors when evaluating the plan
quality. Although the post-processing step minimizes the treatment time, the final gantry
speed and thus treatment time depend on the apertures and fluence rates that are already
determined. We want to, in the future, incorporate constraints that impose upper bounds on
the treatment time and total MU so as to explore the tradeoff between the objective value
and these other quality measures.
Finally, we would like to be able to include transmission effects in the pricing problems,
121
so that we can more accurately evaluate the prices of potential apertures. However, this
means that the pricing problem cannot be solved with the current method anymore, and we
will need to look for other appropriate methods.
5.2 Treatment planning for VMATC
In the optimization of VMATC plans, our method for finding the apertures is very local
in nature. In each iteration the selection is only based on changes in the leaf setting in one
row. We would like to study algorithms that considers multiple leaf rows at a time so that
we can search a larger area of the feasible region.
Moreover, in the current leaf setting optimization process, we have only studied one de-
terministic strategy for determining the sequence of control points and leaf rows. There are
potentially alternative deterministic strategies, as well as strategies that involve randomiza-
tion in this process. We would like to test there strategies, compare them to the current
approach, and determine the best option to be used in the optimization process.
Furthermore, the optimal way of performing the refinement step, which theoretically pro-
vides better solutions than the heuristic approach used currently, is too slow to be practically
feasible. Exploring parallel solvers to speed up the solution of the optimization problems
can benefit the solution quality.
The prostate cancer cases we tested are relatively less complicated compared to cancer
sites such as head and neck, which sometimes involves multiple targets with different target
prescription dose levels. It may not be true anymore that one starting simplex works for
different cases. In that case, finding a good treatment plan in small amount of tests may
become a bigger challenge. It will be interesting to see how the current strategies perform
for a different set of cases.
Finally, the experiments in Chapter III showed similar qualities for VMATC plans com-
pared to the corresponding full VMAT plans. These results are highly algorithm dependent,
and cannot be generalized to arrive at the same conclusions about these treatment modali-
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ties, since we cannot solve either treatment planning problem to optimality. However, they
do reveal that the current VMATC plans are of high quality. It will be interesting to see the
same comparison if we restrict VMATC even further, and require that they use the same
amount of treatment time and/or total MU compared to the VMAT plans.
5.3 IMRT plan optimization under uncertainty
The dynamic sampling procedure used in solving the stochastic optimization model is
slow, as it needs the solution from multiple optimization problems to generate a bound on
the true objective. We would like to explore other implementation options, such as parallel
computing, to make it more practical in the clinical setting.
The current uncertainty scenarios only include rigid shifts in the patient setup position.
It may be beneficial to also take geometry changes into account in the uncertainty models.
This, however, will require a thorough understanding of the potential variations in the sizes
and locations of the patients’ internal structures. Studying the variations in the patient
population with the same cancer type that underwent the same type of treatment can help
us extract information in such modeling attempts. Moreover, we would like to study the
number of samples used in approximating the random setup error. The number should be
sufficiently large to be an appropriate approximation, and ideally be determined through a
less arbitrarily process.
Finally, our experiments showed that under the adaptive optimization framework, the
emphasis of the solutions shifts away from the cumulative dose penalty, and towards the per-
fraction dose penalty as more fractions are delivered. It is important to be able to quantify
this tradeoff, and investigate modifications to our model to take advantage of it. We want
to also study alternative models that can benefit the treatment plan under the adaptive





Relationship between Moving Speed of Radiation Field
Edge and Moving Speed of MLC Leaf
The isocenter plane in radiation therapy is defined as a plane perpendicular to the ray in
the center of a beam that crosses the center of the target. The distance from the radiation
source to the isocenter plane, called SAD, is usually much larger than the size of the target,
therefore the radiation rays emitted from the source are usually considered to be parallel to
each other. However, the fact the source is a point means that the rays are not parallel, or
perpendicular to the treatment machine’s isocenter plane. The primary consequence is that
the positions of the leaf ends are not the same as the position of the radiation field edges.
Moreover, the speed at which the leaves move are not equal to that of the radiation field
edge.
As shown in Figure A.1, when the leaf is at position A which is at a distance w1 from
the center of the beam, the edge of the radiation field on the isocenter plane is at W1. Let







Now if the leaf moves to a point B w2 away from A, a similar analysis shows that the
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In other words, the radiation field edge moves faster than the speed of the leaf movement by
a factor of SAD
SCD
.
This means that any aperture formed by the MLC is larger when projected to the isocen-
ter plane. Since we are interested in the radiation exposure at the isocenter plane where the
patient is located, we can use the projected leaf speed, i.e., the radiation field edge speed,
instead of the actual leaf speed in the optimization problem. Let v̂ be the maximum physical
MLC leaf speed, the maximum projected leaf speed can then be calculated as:
v = v̂ · SAD
SCD
.
Doing this will result in all “leaf positions” being radiation field edge positions, and
“apertures” being exposed radiation field shapes. These can be easily converted back to the
corresponding MLC leaf positions at the end of the optimization process.
Note that here we made an approximation that the radiation field edge is defined by
the ray that passes the tip of the leaf, whereas the ray that is tangent to the leaf is usually
slightly closer to the beam center. The difference in radiation field edge position is shown in
Figure A.2 as the distance between D and E. Because SAD W , we can assume that angle
∠CSD = ∠CSE = θ. Let R be the radius of the leaf end, we have:
x = w +R−R cos θ














SCD +R sin θ
=
w · SAD +R (1− cos θ) · SAD
SCD +R sin θ
=
W · SCD +R (1− cos θ) · SAD
SCD +R sin θ
The difference between X and W equals:
W −X = W − W · SCD +R (1− cos θ) · SAD
SCD +R sin θ
=
WR sin θ −R(1− cos θ) · SAD
SCD +R sin θ
.
Because SAD  W , cos θ is close to 1 and sin θ is close to 0. As result, W −X is also close
to 0.
Therefore we define the radiation field edge with the ray that passes the tip of the leaf.
This allows us to use a simple representation of the projected leaf speed in the optimization
problem, without unduly compromising the quality of the solution.
Figure A.1: A schematic diagram of the source, MLC leaf, and isocenter plane
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Figure A.2: A ray passing the MLC tip and a second ray tangent to the leaf end
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APPENDIX B
Derivation of Transmission Coefficient for a Beamlet
Outside the Radiation Field
Part of this section follows the analysis in Boyer and Li (1997). Consider two rays `1
and `2 emitted from the source, with `1 tangent to the leaf end, and `2 intersecting the leaf












Following a similar analysis as Appendix A, we can calculate the length of the projection
of d′ on the isocenter plane
δ = d′ · SAD









SCD +R sin θ
(B.1)
The Beer-Lambert law describes that the radiation intensity I after transmitted through a
material of thickness y depends on the initial intensity I0 and the material-specific coefficient
129





For each material, we can define a Half Value Thickness (HVT) as the thickness required to




⇒ λ = ln 2
HVT
.
For ray `2 the attenuation factor then equals:







⇒ ` = − lnα
ln 2
· HVT. (B.2)
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δ2 γ21 − 2Rδ γ1 = −γ22 lnα2.





























Now we can calculate the transmission coefficient for a beam that lies between τ1 and τ2

























































Convergence of the SAA Approach
In this section we show that when m, M , and K → ∞, the objective function value of
problem (SAA), namely gm, as well as the bounds L(M) and U(K) converge to the optimal
objective value g∗.
First note that as M and K →∞, the estimates L(M)→ E[gm] and U(K)→ E[G(x̂,p)].
If the solution to the (SAA) problem, namely x̂, converges to the optimal solution x∗ of (P),
it then follows that gm converges to g
∗, and both E[gm] and E[G(x̂,p)] converge to g∗, and
as a result L(M) and U(K) also converge to g∗. We will show below that, as m → ∞, the
solution of the (SAA) problem converges to the solution of (P).
We start by examining the general problem (SP) and (SPm). Robinson (1996) showed
that with probability 1, a minimizer of (SPm) will, for large m, exist and be as close as
desired to the set of minimizers of (SP) if the following three conditions are satisfied:
1. Y is compact





i) converges to Ef(y, ξ) uniformly with probability 1.
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Instead of proving Condition 2 directly, we can take advantage of the Uniform Conver-
gence Theorem, which states that:
Uniform Convergence Theorem. If fn is a series of continuous functions that uniformly
converges to a function f . Then f is continuous.
If we can prove that Condition 3 is satisfied, we can alternatively show that the following





i) is continuous for all m > 0.
We leave the first two conditions aside for now, and first tackle the third condition. This
proof can be done using the following theorem:
Theorem. (Jennrich (1969)) If
• Y is compact
• f(y, ξ) is continuous at each y ∈ Y for all ξ, and a measurable function of ξ at each y
• there exists a dominating function d(·) such that E[d(ξ)] <∞, and







f(y, ξ)− E[f(y, ξ)]
∥∥∥∥∥ → 0 almost surely,
which implies uniform convergence.
The first two conditions in the Theorem above are easy to see for our problem, since the
feasible region X is compact, and given the realized path p(N−n), the objective function is
the sum of quadratic terms, and is therefore continuous. For the last condition, note that
assuming the setup error of the patient is restricted to be within a certain region, i.e., large
displacement will be detected and corrected, our objective function is bounded above by a
finite number, sayM, and below by 0 . Therefore if we define d(·) =M, the third condition
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will also be satisfied. As a result, we know that as m→∞, the solution to problem (SAA)
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